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Silica nanoparticles (SiO2) have utility in a wide range of applications, such as 
biologic delivery platforms, imaging and diagnostic agents, and targeted therapeutic 
carriers. Recent improvements in regulating the geometry, porosity, and surface 
characteristics of SiO2 have further facilitated their biomedical applications. Concerns 
however remain about the toxic effects of SiO2 upon exposure to biological systems. The 
impacts of geometry, porosity, and surface characteristics of SiO2 on cellular toxicity and 
hemolytic activity were explored. It was shown that surface characteristics and porosity 
govern cellular toxicity. The cellular association of SiO2 increased in the following order: 
mesoporous SiO2 (aspect ratio 1, 2, 4, 8) < amine-modified mesoporous SiO2 (aspect 
ratio 1, 2, 4, 8) < amine-modified nonporous Stӧber SiO2 < nonporous Stӧber SiO2. 
Geometry did not seem to influence the extent of SiO2 cellular association. Hemolysis 
assay showed that the hemolytic activity was porosity- and geometry-dependent for 
pristine SiO2 and surface charge-dependent for amine-modified SiO2.  
The acute toxicity, biodistribution, and pharmacokinetics of SiO2 of 
systematically varied geometry, porosity, and surface characteristics were evaluated in 
immune-competent mice when administered intravenously. Results suggest that in vivo 
toxicity, biodistribution and pharmacokinetics of SiO2 were mainly influenced by 
nanoparticle porosity and surface characteristics. The maximum tolerated dose (MTD) 
increased in the following order: Mesoporous SiO2 (aspect ratio 1, 2, 8) at 30 – 65 mg/kg 
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< amine-modified mesoporous SiO2 (aspect ratio 1, 2, 8) at 100 – 150 mg/kg < 
unmodified or amine-modified nonporous SiO2 at 450 mg/kg. The adverse reactions 
above MTDs were primarily caused by the mechanical obstruction of SiO2 in the 
vasculature that led to congestion in multiple vital organs and subsequent organ failure. 
The nanoparticles were taken up extensively by the liver and spleen. Mesoporous SiO2 
exhibited higher accumulation in the lung than nonporous SiO2 of similar size. This 
accumulation was reduced by primary amine modification. Increasing the aspect ratio of 
amine-modified mesoporous SiO2 from 1 to 8 resulted in increased accumulation in the 
lung.  
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Silica-based nanomaterials have attracted much attention in biomedical 
applications as cell markers, gene transfection agents, imaging moieties, as well as drug 
carriers [1-5]. They possess a variety of unique properties, such as ease of synthesis, 
availability of surface modification, robust mechanical properties, and relatively inert 
chemical composition [6, 7]. Recent advances in manipulating the geometry, porosity, 
and surface characteristics of silica nanoparticles (SiO2) have further enabled their utility 
in nanomedicine [8-11]. Despite these advantages, the influence of physicochemical 
factors such as geometry, pore size, and surface functional groups of SiO2 still needs to 
be carefully examined for successful utility of these constructs in biomedical applications 
[12].  
The variations in physicochemical characteristics play a crucial role in 
determining the compatibility of SiO2 with biological systems and hence their 
development for diagnostic or therapeutic applications [13-17]. Previous studies have 
revealed that biodistribution of nonporous SiO2 varies according to particle size and only 
smaller SiO2 of 70 nm in diameter accumulated in the placenta and fetus of pregnant 
mice compared to 300 nm or 1,000 nm nanoparticles [13]. Other studies on particle size
2 
 
and toxicity relationship using a similar set of  nonporous SiO2 demonstrated that 70 nm 
nanoparticles induced liver injury at 30 mg/kg animal weight while 300 nm or 1,000 nm 
SiO2 exerted no adverse effect at 100 mg/kg [14, 15]. The difference in the toxicity level 
could be due to the differential biodistribution pattern of SiO2 in mice since studies have 
shown that smaller SiO2 tend to have higher accumulation in the reticulo-endothelial 
system (RES) and cause specific organ toxicity [16]. It has also been shown that surface 
modification of 70 nm SiO2 by either primary amine or carboxylic moieties prevent 
fetotoxicity even though the modified SiO2 were found in placenta and fetus of mice [13]. 
The surface modification of SiO2 could also alleviate liver injury and avoid hepatic 
fibrosis [17]. Thus, it is of great interest to systematically evaluate the interdependent 
influence of geometry, porosity, and surface functionality on toxicity of SiO2.  
Recent studies have demonstrated that geometry of nanocarriers can influence 
their circulation half-life and other pharmacokinetic parameters [18-21]. For example, 
pegylated polymeric micelles of long, filamentous shape persisted in the circulation up to 
1 week after intravenous injection, approximately 10 times longer than their spherical 
counterparts [18]. It was suggested that the spherical micelles were taken up by the cells 
more readily than the long filaments under fluid flow conditions since the cellular entry 
of the latter was opposed by flow [18]. Cyclic polymers composed of α-cholo-ε-
caprolactone and ε-caprolactone, which had molecular weights greater than the renal 
threshold, showed longer blood circulation time in mice than linear polymers of similar 
composition and comparable molecular weight [19]. This effect was attributed to the fact 
that linear polymers traverse nanopores in glomeruli by end-on motion of one chain end, 
while cyclic polymers transit through by entering the pores with two chain segments 
3 
 
since they lack chain ends [19]. While the studies above relate to more flexible polymeric 
systems, the influence of geometry on biological fate has also been studied for more rigid 
nanoparticles. For example, it has been shown that the anti-intercellular adhesion 
molecule 1 elliptical polystyrene disks (0.1 × 1 × 3 µm) had higher endothelial targeting 
specificity in the lung than spheres of different sizes (0.1, 1, 5 µm) [20]. Further, it has 
previously been demonstrated that pegylated gold nanorods (10 × 45 nm, 1.13 mV) 
exhibited longer blood circulation half-life and higher tumor accumulation than pegylated 
gold nanospheres (50 nm, -27.1 mV) in orthotopic ovarian tumor xenograft mice [21]. 
These studies suggest that geometry and carrier architecture can influence the in vivo 
behavior of nanoscale platforms. However, much needs to be examined in this area since 
factors such as porosity and surface characteristics can further influence biodistribution 
and pharmacokinetics. 
This dissertation is centered on the systematic variation of SiO2 geometrical 
features, porosity, and surface chemistry to understand their influence on nanoparticle 
toxicity and biodistribution. The results can provide baseline information about how to 
rationally engineer SiO2 to minimize toxicity. In the long term, such an approach can be 
used for the design and development of advanced drug delivery systems involving SiO2. 
1.2 Hypothesis and aims of this dissertation 
The global hypothesis of this dissertation is that by tailoring the shape, porosity, 
and surface functionality of SiO2, their in vitro and in vivo toxicity, biodistribution, and 
pharmacokinetics can be altered to reduce adverse effects in potential biomedical 

















Specific Aim 1:  To synthesize and characterize nonporous and mesoporous SiO2 
of distinct geometrical features and surface properties, and to evaluate their cellular 
toxicity and blood biocompatibility. 
  Specific Aim 2: To evaluate the in vivo toxicity of systemically injected-SiO2 with 
different shapes, porosity, and surface chemistry through maximum tolerated dose 
identification, hematology, and histology. 
Specific Aim 3: To evaluate the biodistribution and pharmacokinetics of SiO2 of 
various physicochemical features and to relate these parameters with in vitro and in vivo 
toxicity. 
1.3 Scope and organization of this dissertation 
Chapter 2 of this dissertation provides a current review of the literature on 
development of nanotoxicology as a field with a focus on the toxicity of SiO2 on 
biological systems. The origin of nanotoxicology and its implication in public health and 
research application, multiple nanoparticle systems toxicity issues, and factors that 
contribute to the onset of toxicity are discussed with focus on SiO2 physicochemical 
parameters and the resultant toxicity impact. Chapter 3 describes the synthesis and 
characterization of a series of nonporous and mesoporous SiO2 with distinct geometrical 
features and surface properties and evaluates their effects on cellular toxicity and blood 
biocompatibility [22]. In Chapter 4, maximum tolerated doses (MTDs) of selected SiO2 
were determined in vivo and the adverse reactions beyond MTDs were examined and 
related with the physicochemical properties of SiO2 [23]. In Chapter 5, the biodistribution 
and pharmacokinetics of SiO2 as a function of geometry, porosity, and surface 
characetristics in immune-competent CD-1 mice was discussed and correlated with in 
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vitro and in vivo toxicity [24]. In Chapter 6, the key findings of this dissertation are 
summarized and comments are made about the future direction for this research. In 
Appendix A, the cytotoxicity of silica nanotubes (SNTs) was evaluated in a pilot study as 
a function of size and surface charge. Appendix B describes synthesis and 
characterization of silica-coated gold nanorods as alternative elongated-shaped silica 
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Advances in nanotechnology have led to the development of novel nanoparticles 
for pharmaceutical applications aimed at improving diagnosis and treatment of diseases 
and the quality of human life [1, 2]. Many nanoparticle systems have found uses in drug 
delivery, imaging, and other applications [2]. However, the fast growing pace in 
nanotechnology has also brought to bear short- and long-term safety issues [3, 4]. From 
this perspective, it is essential to carefully study the toxicity profiles of nanoparticles and 
how such adverse effects relate to their function.  
Recent advances in synthesis and fabrication have enabled the production of 
nanoparticles with high control over geometry, porosity, and surface characteristics, and 
other physicochemical features [5]. By utilizing top-down or bottom-up synthetic 
strategies, nanoparticles with distinct shape, porosity, or surface functionality are readily 
produced at a large scale in a time-efficient manner [6]. Considering their potential 
applications in various areas, it is intuitive to evaluate the toxicity aspects and to engineer 






Nanomaterials such as silica and titanium dioxide nanoparticles and carbon 
nanotubes are widely used in electronics, catalysis, foods, cosmetics, and drug delivery [7, 
8]. The increasing use of nanomaterials has raised concerns for their impact on public 
health [9]. It has been reported, for example, that carbon nanotubes can induce 
mesothelioma-like lesions in mice, similar to those induced by asbestos [10]. It is 
necessary to evaluate the toxicity of nanoparticles which can also help to identify the 
origins of certain human diseases due to nanoparticle exposure.  
2.2.1 Origin 
2.2.1.1 Environmental hazards 
With the industrialization of modern society, human beings are subject to 
exposure of nanosized particulates either by occupational exposure or from the 
environment [11].  Contamination in the ambient environment is an important public 
health issue. Epidemiologic studies reveal that increased level of ambient nanoparticles is 
associated with an increase in the incidence of respiratory and cardiovascular diseases 
[12]. However, it is particularly difficult to identify a direct linkage between a specific 
human disease and exposure to ambient particulates since their composition, size, and 
other physicochemical parameters are complicated and variable. By engineering 
nanoparticles and correlating structure and physicochemical properties with biological 
effect, it is possible to find correlations between potential adverse effects to humans on 
one hand and particulate exposure on the other.  For example, it has been reported that 
inhalation of manufactured SiO2 causes pulmonary and cardiovascular symptoms in mice, 
including pulmonary inflammation, myocardial ischemic damage, arterio-ventricular 
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blockage, increase in fibrinogen concentration and blood viscosity [13]. The risk of 
physiological damage increases in the order of adult < young < old individuals, indicating 
the increased susceptibility of older populations to diseases upon exposure to 
environmental hazards [13]. Studies of nanoparticles with known parameters may 
provide information about the correlation between the epidemiologic findings and the 
effects of environmental particulates on human health. 
2.2.1.2 Nanoparticles as delivery systems 
Previous research on toxicology of nanosized materials is largely focused on the 
effects of nanoparticles that enter the body accidentally. Nowadays, toxicology studies 
have also been applied to major drug and imaging agent carriers that are used by patients 
or in clinical trials. A number of pharmaceutical products that use nanoparticulates have 
been approved for commercial production, or are at different stages of clinical trials 
(Table 2.1) [14], or are undergoing preclinical studies (Table 2.2) [15]. The emergence of 
novel methods to fabricate or manipulate nanoparticles is accompanied by the recognition 
of underlying toxicity issues associated with their utilization. These include toxicity 
mechanisms that are related to frustrated phagocytosis, changes in protein structure and 
function, immune activation, fibrogenesis and tissue remodeling, blood clotting, vascular 
injury, neurotoxicity, and other adverse effects (Table 2.3) [16]. Research shows that the 
compatibility of nanoparticles with biological systems is mainly determined by their 
physicochemical properties [17]. Modifying these factors can effectively change the 




Table 2.1 Examples of nanoparticles for diagnostic and therapeutic applications which 
have been approved by the FDA or are currently in clinical trials (adapted from [14]) 
 


















Solid tumors Cyclosert Phase I Insert 
Therapeutics 




Iron oxide Tumor 
imaging 




Solid tumors Aurimune Phase II CytImmune 
Sciences 
Gold nanoshell Solid tumors AuroLase Phase I Nanospectra 
Biosciences 
Quantum dot Melanoma Cornell dot Phase I Hybrid Silica 
Technologies 





















Gold 10, 50, 100, 250 nm Mice IV 24 h 
Silver 2 nm, BSA coated Rats IP 7 d 
Ferric oxide 144 nm Mice Pulmonary 50 d 
Quantum 
dots 
13 nm  Mice IV 28 d 
Carbon 29.7 nm Rats Pulmonary 24 h 
Silica 20 nm, -25.5 mV, 
PEG modified 
Mice IV 24 h 





PLGA 133.5 nm, -54.2 mV Mice IV 24 h 
f-SWNTs 1 × 300 – 1000 nm, 
ammonium 
functionalized 
Mice IV 24 h 
PLGA, poly(lactic-co-glycolic acid); f-SWNTs, functionalized single wall carbon 




























Table 2.3 Experimental summary of major toxicological pathways which are associated 
with nanomaterial toxicity (adapted from [16]) 
 
Toxicological pathway Nanomaterials 
Membrane damage/leakage/thinning Cationic nanoparticles 
Protein binding/unfolding responses/loss of 
function/fibrillation 
Metal oxide nanoparticles, 
polystyrene, dendrimer, 
carbon nanomaterials 
DNA cleavage/mutation Nano-Ag 
Mitochondrial damage Ultrafine particles, cationic 
nanoparticles 
Lysosomal damage: proton pump activity/lysis/frustrated 
phagocytosis 





Metal oxide nanoparticles, 
carbon nanotubes 
Fibrogenesis and tissue remodeling injury Carbon nanotubes 
Blood platelet, vascular endothelial and clotting 
abnormalities 
SiO2 
Oxidative stress injury, radical production, glutathione 
depletion, lipid peroxidation, membrane oxidation, protein 
oxidation 
Ultrafine particles, carbon 




























2.2.2 Current stage and focus of nanotoxicology 
To date, the development of nanotoxicology has been centered on elucidating the 
relationship of nanoparticle physicochemical properties with their biological activity and 
correlation of in vitro observation with in vivo outcome (Figure  2.1) [16]. With an 
increased recognition of the need for effective approaches to control the impact of 
emerging nanotechnologies on the environment and human health, it is crucial to develop 
a framework to link research on the risk associated with nanotechnology to the decision-
making needs of manufacturers, regulators, consumers, and other stake holder groups 
(Figure 2.2) [18]. Considering the potentially high uncertainties associated with 
nanoparticles, research efforts should be directed to providing information that is most 
meaningful to these groups. The research on nanotoxicology should be prioritized in the 
direction that is responsive to the recommendations on managing risks and impact of 
nanomaterials on the environment and human health. 
2.3 Nanosystems in biomedical application and their implication in toxicity 
The rapid developments in nanotechnology have raised the public‟s awareness of 
safety threats of the nanoparticle systems. The research community has stepped up efforts 
in looking into the toxicity issues of nanoparticles that are frequently used in industrial or 
academic settings [19, 20]. However, certain key issues should be realized for the fair 
judgment and decision making about nanoparticle utilization with a focus on its 
pharmaceutical application. First, nanoparticles could be administered through various 
routes, such as oral, topical, intravenous, intraperitoneal, epidural, etc. The toxicity of 




Figure 2.1 Elements of predictive toxicological paradigm for nanomaterial hazard testing. 
A predictive toxicological approach is defined as establishing and using in vitro 
mechanisms and pathways of injury that are directly related to the physiochemical 
properties of nanomaterials as well as to disease mechanisms in vivo. The in vivo output 
is used to validate the in vitro screening method as being “predictive” and therefore valid 
for screening large batches of materials to obtain quantitative structure-activity 










Figure 2.2 Framework for prioritizing research into the impact of nanomaterials on the 
environment and human health. The process could be viewed as starting at manufacturing 
companies, where designers and developers need to select a particular technology for a 
given task. Experts assess each proposed technology relative to the decision criteria 
through probability distributions based on experimental science or experience. This 
model integrates all of this information by comparing the technologies to determine 
which performs best on each criterion, and computes an overall preference score across 
criteria for each technology for each stakeholder group. This investigation explores the 
uncertainty in the Multi-criteria Decision Analysis (MCDA) results to determine how 
new information gained through research might impact the selection decision. If the 
overall score for a particular stakeholder group can be significantly improved by 
establishing technological details with certainty, then a research program that is capable 







mesoporous silicates cause no adverse reactions through subcutaneous injection while 
they cause severe systemic toxicity including casualty [21]. Second, the dose selected 
could substantially influence the responses from biological systems [22]. If one type of 
nanoparticle leads to adverse reactions at high doses, it does not mean it is more toxic 
than the other types of nanoparticle showing no toxicity at low doses, although it could 
give a false impression that the nanoparticles showing no toxicity are safer. Third, the 
nanoparticles should be fully characterized and free of contaminants prior to any 
biological evaluation [23]. Otherwise, the toxicity outcome might be attributed to an 
irrelevant factor or may not be due to the nanoparticle itself. Fourth, time length in the 
study could affect toxicity level as some symptoms take time to form in order to be 
detected by clinical techniques. To sum up, in order to obtain accurate and 
comprehensive understanding on nanoparticle safety, it is essential to compare 
nanoparticle toxicity under equal conditions to generate valuable guidelines about 
designing nanoparticles with minimum adverse effects. 
2.3.1 Polymeric nanosystems 
Polymer-based delivery systems have been widely used as gene, drug, or dye 
carriers because of their potential long circulation half-lives and ready uptake by cells [24, 
25]. However, such carriers can impose substantial toxicity risks [26, 27]. One such 
example is the use of poly(amido amine) dendrimers as drug delivery or diagnostic 
imaging systems due to the capacity to control the size and surface functionalities of 
these constructs [28].  In order to evaluate the influence of size and surface functionality 
of dendrimers on systemic biocompatibility, dendrimers were given to immune-
competent mice via intravenous injection [27]. A clear trend in in vivo toxicity was 
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observed based on surface functionalities. Amine-terminated dendrimers caused 
hematological complications such as disseminated intravascular coagulation, whereas 
carboxyl- and hydroxyl-terminated dendrimers of similar sizes were tolerated at 50-fold 
higher doses [27]. These findings set caution for employing amine-terminated polymeric 
systems for systemic administration and have important implications in the safety of 
nanoparticles in biomedical application. 
2.3.2 Gold nanoparticles 
Gold nanoparticles are generally considered as biocompatible materials and are 
used in clinical trials as drug carriers or engineered devices that transform light energy 
into heat in hyperthermia treatment for solid tumors [29]. It has been reported that mice 
intravenously injected with gold nanoparticles (1.9 nm in diameter) at 2.7 g Au/kg 
survived over 1 year without signs of toxicity [30]. The LD50 for this material is 
approximately 3.2 g Au/kg mice. Mice subject to intravenous injection at the dose of 10 
mg Au/mL blood showed normal haematology and blood chemistry for 30 days with no 
histological evidence of toxicity observed in any animal [30]. Biodistribution results 
show that the highest tissue gold concentration 15 minutes after injection was in kidneys, 
followed by tumor, liver, and muscle. The tumor:muscle gold ratio increased from 3.4 at 
15 minutes to 9.6 at 24 hours, enabling the clear delineation of the tumor as X-ray 
contrast agents [30]. However, for gold nanorods which are synthesized out of the 
surfactant template-assisted method using a cationic surfactant such as 
cetyltrimethylammonium bromide (CTAB), they may be toxic to biological systems since 
they could perturb cell membrane if the surfactant is not completely removed [31, 32]. 
The salt HAuCl4, the nanoparticle substrate, were toxic to the cells at ∼ 10 nM 
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concentrations [31]. Extra attention should be paid to utilizing nanosystems for which 
toxic reagents are used in the synthesis, and complete purification of nanoparticles is a 
key step for any biological work. 
2.3.3 Magnetic nanoparticles 
Super paramagnetic iron-oxide nanoparticles have unique magnetic properties and 
are used as contrast agents in magnetic resonance imaging or as colloidal nanocarriers for 
targeted drug delivery in diagnosis and therapy [33]. In addition to the excellent magnetic 
properties, iron-oxide nanoparticles can be decomposed into free iron ions which can 
further incorporate in the hemoglobin of erythrocytes and be removed through normal 
iron recycling pathways [34]. The ultrasmall superparamagnetic iron-oxide contrast 
agents have been subject to safety evaluation at the dose of 0.8, 1.1, and 1.7 mg Fe/kg in 
phase II clinical trials [35]. The adverse events most frequently observed were dyspnea 
(3.8%), chest pain (2.9%), and rash (2.9%) among the participating patients. There were 
no clinically significant effects on vital signs, physical examination, and laboratory 
results. At dose administered, iron-oxide nanoparticles are considered as generally safe 
and well-tolerated magnetic resonance contrast agents. 
2.3.4 Silica nanoparticles 
SiO2 are considered as potential therapeutic delivery systems because of their 
tailored pore structure, chemical stability, and ease of chemical modification [36]. The 
biocompatibility of mesoporous silicates of particle sizes 150 nm, 800 nm, and 4 mm and 
pore sizes of 3 nm, 7 nm, and 16 nm, respectively, has been examined in animals through 
different administration routes [21]. Following subcutaneous injection of silicates, the 
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amount of residual material decreased progressively with good biocompatibility, as 
evidenced by histology over a period of 3 months. In contrast, intraperitoneal and intra-
venous injections in mice resulted in death or euthanasia, probably due to pulmonary 
thrombosis [21]. Results suggest that local tissue reaction to mesoporous silicates was 
benign while they caused severe systemic toxicity. This study emphasizes the importance 
of chemical modification of SiO2 in influencing systemic toxicity in animals. 
2.3.5 Other nanosystems 
The above are just a few examples of nanomaterials and the influence of 
physicochemical properties on toxicity. Other examples include quantum dots, carbon 
nanotubes, titanium dioxide nanoparticles, silver nanoparticles, silicon nanoparticles, etc. 
The detailed discussion of the properties and biological fate of all these constructs is 
beyond the scope of this dissertation. Discussion of two other examples, i.e., quantum 
dots and carbon nanotubes is outlined below. 
Quantum dots are inorganic semiconductor fluorophores comprised of atoms of 
elements from groups II to VI. They are currently emerging as versatile tools for 
biological imaging [37, 38]. However, the chemical stability of quantum dots in 
biological systems and the resultant toxicity issue is a serious challenge in its clinical 
development [39]. The use of biocompatible chemistries and reduction of toxicity are 
necessary in accelerating the utility of these nanoparticles in biomedical applications such 
as tumor imaging [40].  
Carbon nanotubes are cylindrical graphene sheets which have potential 
applications in hyperthermic ablation of cancer tissues due to the strong optical 
absorption in the NIR wavelength region [41] and in drug delivery because of their high 
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surface areas [42]. However, there are concerns for the biodistribution and toxicity of 
carbon nanotubes in vivo, as they have shown high accumulation in liver and kidney and 
insufficient renal excretions [43]. There are also concerns about impurities such as non-
nanotube carbon, amorphous carbon, metal residues (iron, nickel, yttrium), etc., that are 
associated with carbon nanotubes during fabrication [44, 45] and the lack of complete 
removal of these contaminants could result in potential complications in the use of carbon 
nanotubes in vivo [46]. 
2.4 Effect of nanosystem physicochemical properties on toxicity 
Nanoconstructs can possess variations in their physicochemical characteristics 
such as size and size distribution, core composition and structure, surface functionality, 
porosity, and geometry. These parameters have substantial influence on biological 
systems, as depicted in Figure 2.3 [14]. 
2.4.1 Size 
Size is a major factor in influencing nanoparticle cellular interaction and in vivo 
behavior. In a study comparing the hemolysis of nonporous SiO2 ranging from 25 to 225 
nm in diameter, it was shown that smaller particles have higher hemolytic activity than 
the larger ones [35]. This phenomenon is attributed to the larger surface area of the 
nanoparticles [47]. In another study, it was shown that cellular association of mesoporous 
SiO2 by cancerous epithelial cells is particle size-dependent and the maximum uptake by 
cells occurs at the size of 50 nm among all nanoparticles tested (50 – 280 nm) [48]. The 
cytotoxicity of monodisperse amorphous SiO2 with the same morphology was strongly 




Figure 2.3  Nanoparticle physicochemical characteristics influence biocompatibility 
(route of uptake and clearance, green; cytotoxicity, red; and RES recognition, blue) as a 










than the larger ones. It was concluded that the surface area of tested particles was a 
critical parameter in determining toxicity of amorphous SiO2. However, how variations in 
surface area influence the toxicity outcome is still not fully understood and warrants 
further investigation. 
On the basis of physiological parameters such as hepatic filtration, tissue 
extravasation, tissue diffusion, and kidney excretion, it is clear that particle size is a key 
factor in determining nanoparticle distribution in vivo [50]. The tissue distribution of gold 
nanoparticles is size-dependent with 15nm nanoparticles showing the most widespread 
organ distribution including blood, liver, lung, spleen, kidney, brain, heart, and stomach 
while 200 nm gold nanoparticles showed limited presence in organs including blood, 
brain, stomach, and pancreas [51]. Nanoparticles used for targeted delivery to solid 
tumors are defined to be in the range of 10–100 nm [35]. The lower limit is based on the 
threshold of the glomerular capillary wall for first-pass elimination by kidneys estimated 
at 10 nm or less. The upper limit on size is not well defined at this time. The “enhanced 
permeability and retention effect” (EPR) describes the phenomenon that nanoparticulate 
systems exit from the leaky blood vessels and accumulate in the tumor due to the 
impaired lymph system draining function and relative large size of nanoparticles [36]. 
2.4.2 Porosity 
Porosity of inorganic nanoparticles is usually generated in the process of the 
template-assisted synthesis and template removal by chemical extraction or etching 
approaches. Mesoporous SiO2 showed lower hemolytic activity than their nonporous 
counterparts of similar size, probably due to fewer silanol groups on the cell-contactable 
surface of mesoporous SiO2 [47]. The level of hemolysis by mesoporous SiO2 increased 
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when the pore structure was damaged by aging in salt solutions [47]. It is clear that the 
pore structure and stability is an important factor in determining the blood 
biocompatibility of nanoparticles. Since an array of proteins is present when SiO2 are 
exposed to physiological media, it is expected that differential protein adsorption will 
occur to SiO2 of various porosities and the biological outcome could be drastically 
different [52]. 
2.4.3 Geometry 
The geometrical features of nanoparticles are usually formed as self-assembled 
micelles, like filomicelles [53]; with the assistance of surfactants at different 
concentrations, such as gold nanorods [54]; with physical compression to original 
particles, like polystyrene beads of different shapes [55, 56]; or in the template mold, 
such as SNTs [57]. The filomicelles, resembling flexible filaments, had prolonged blood 
circulation time up to 1 week post-intravenous injection compared with spherical systems 
of similar chemistry and composition [53]. This phenomenon is probably due to the 
reduced uptake by cells since filomicelles are extended by the circulation flow, 
demonstrating the merits of long shape features in vivo.  
The influence of geometry of SiO2 on cellular uptake and toxicity on epithelial 
and phagocytic cells has been analyzed using three types of amine-terminated SiO2, 
namely spheres (178 ± 27 nm), worms (232 ± 22 nm × 1348 ± 314 nm), and cylinders 
(214 ± 29 nm × 428 ± 66 nm) [58]. The findings of the study suggest that geometry does 
not play a dominant role in the modes of toxicity and uptake of these particles in the size 
range studied.  
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Spherical and rod-shaped gold nanoparticles with surface PEG chains were 
injected intravenously to nu/nu mice bearing orthotopic ovarian tumors to compare their 
biodistribution pattern in vital organs [59]. Gold nanorods (10 × 45 nm, 1.1 mV) had 
longer circulation time, lower liver uptake, and higher tumor accumulation compared 
with their spherical counterparts (50 nm, -27.1 mV) (Figure 2.4). In vitro results showed 
that gold nanorods were taken up to a lesser extent by macrophages than nanospheres 
(Figure 2.4). Protein interaction analysis revealed that gold nanospheres exhibited more 
extensive interaction with proteins than nanorods, probably due to their more negative 
charge and enhanced interaction with lysine residues from proteins (Figure 2.4). This 
association with proteins might have led to the increased uptake of nanospheres by RES 
and reduced circulation time in vivo compared with nanorods.  
2.4.4 Surface characteristics 
Surface characteristics can have a profound influence on the interaction of 
nanoparticles with the local environment, leading to downstream distribution outcome or 
toxicity effects. Such characteristics are always manipulated by addition of steric 
stabilization, changes in surface charge, or addition of targeting ligands. Surface 
modification on SiO2 has been shown to reduce their systemic toxicity compared to the 
pristine counterparts [59, 60]. For example, it has been reported that amorphous SiO2 
with diameter of 70 nm caused structural and functional abnormalities in the placenta on 
the maternal side when injected intravenously into pregnant mice and abolished when the 
surface of nanoparticles were modified with carboxyl and amine groups [60]. Previous 
studies also showed that the intravenous administration of pristine SiO2 with a diameter 




Figure 2.4 Summary of gold nanoparticle characterization and their geometry effect in 
vitro and in vivo. A) Transmission electron microscopy (TEM) images of pegylated gold 
spheres and rods. B) Their plasma profiles, distribution in C) liver and D) in tumor as a 
function of time are shown. n = 3 ± standard error. *Significant difference between rod 
and spherical particles p < 0.05. E) Interaction between gold nanoparticles and BSA is 
expressed as quenching efficiency (I0/I), where I0 and I are fluorescence in the absence 
and presence of gold nanoparticles. F) Uptake of gold nanoparticles by RAW 264.7 
macrophages is compared in the presence and absence of serum. R = rod; S = spherical; n 
= 3 ± standard deviation (SD), *p < 0.01 (adapted from [59]). 
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SiO2 led to much less toxicity level and did not cause hepatic fibrosis. These findings 
indicate that the surface characteristics of nanoparticles can change toxicity profiles. It 
has been suggested that the change in surface characteristics influences the interaction of 
nanoparticles with proteins in the blood stream, which leads to alteration in 
hydrodynamic sizes and organ distribution patterns [59].   
In addition, targeting ligands that provide specific nanoparticle–cell surface 
interactions can play a vital role in enhanced cellular uptake. These targeting ligands 
enable nanoparticles to bind to specific cell-surface receptors that are overexpressed by 
target cells and enter cells by receptor-mediated endocytosis. For example, cellular 
uptake and biodistribution of pegylated gold nanorods with or without the cyclic RGDfK 
(Arg-Gly-Asp-D-Phe-Lys) peptide functionalization were tested on DU145 prostate 
cancer cells, human umbilical vein endothelial cells, and in prostate tumor-bearing mice 
[62]. Targeting of the RGDfK surface-modified gold nanorods was confirmed in vitro 
due to selective binding and uptake by endothelial cells. Tumor targeting was not 
observed in vivo, however, probably due to fast clearance of the RGDfK-gold nanorods 
from the blood. It is possible that the presence of strong negative charges from RGDfK 
moieties overrides their targeting ability to the tumor, resulting in RES clearance of this 
system rather than enhanced uptake by the tumor. These findings corroborated with a 
previous study on tumor uptake of elongated gold nanocrystals that were covalently 
bound tumor-targeting peptides [63]. Quantitative pharmacokinetic and biodistribution 
data showed that the use of active targeting ligands on gold nanorods only marginally 
improved the total tumor uptake in comparison with control nanorods in the xenograft 
animal models. These results indicated that mass transport across the tumor vasculature is 
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a rate-limiting step for nanoparticle delivery and its kinetics is largely unaffected by 
active receptor binding [63]. 
2.4.5 Other physicochemical properties 
Other physicochemical properties such as core composition, polymer architecture, 
etc., exert critical effects on biological systems. It was hypothesized that greater degrees 
of nanoparticle “flexibility” improve the binding ability of particles on the cell surface 
[50]. Shell cross-linked nanoparticles possessed a low glass transition temperature (Tg) 
with a fluid-like poly(methyl acrylate) core or a high Tg with a glassy poly(styrene) core 
[64]. The effect of the rigidity of the polymeric core on the in vivo biodistribution was 
evaluated and results showed that high-Tg poly(styrene) core nanoparticles exhibited a 
significantly higher blood residence time compared to the low-Tg poly(methyl acrylate) 
nanoparticles, probably due to the greater flexibility and increased surface interaction that 
the low-Tg core nanoparticles had with the tissues [64]. Cyclic polymers composed of α-
cholo-ε-caprolactone and ε-caprolactone showed longer blood circulation time in mice 
than linear polymers of similar composition and comparable molecular weight (> renal 
filtration threshold) [65]. It is probably due to the fact that linear polymers traverse 
nanopores in glomeruli by end-on motion of one chain end while cyclic polymers transit 
with two chain segments since they lack chain ends, implying the effect of polymer 
architecture on in vivo biodistriubtion and clearance [65]. 
2.5 Synthesis, fabrication, and characterization of silica nanoparticles 
In the past decade, silica-based nanomaterials have attracted much attention in 
biomedical applications as cell markers, gene transfection agents, as well as drug carriers 
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[36, 66-70]. They possess a variety of unique properties, such as ease of synthesis and 
surface modification, robust mechanical properties, and relatively inert chemical 
composition, which make them excellent candidates for biological applications [68]. 
Progress in mold fabrication has further enabled the production of particles with distinct 
shapes [57, 71]. Reports are emerging that particle shape influences cellular uptake and 
biodistribution in vivo [72, 73]. 
2.5.1 Synthesis and fabrication 
2.5.1.1 Top-down method 
The emerging “top-down” fabrication is a robust tool adapted from the 
microelectronics industry for the facile production of tailor-made nanofabricated particles 
[5]. With the assistance of top-down fabrication techniques, the acquiring of detailed 
knowledge of the interdependent effect that key particle physicochemical variables have 
on biological toxicity become feasible. For example, with regard to SNT fabrication, the 
top-down strategy involving a template mold is utilized (Figure 2.5) [57]. First, a porous 
alumina template is prepared by electrochemical anodization on aluminum plate, where 
the pore dimensions could be adjusted from five to a few hundred nanometers in diameter 
and from tens of nanometers to hundreds of micrometers in length. Secondly, thin layers 
of nanomaterial are deposited onto the cylindrical wall of nanopores of an alumina 
membrane including surfaces of membrane through the sol-gel chemistry. Thirdly, the 
layer on the top of the membrane is removed by mechanical polishing. Last, free 
nanotubes are obtained by selectively dissolving the alumina template in 25% phosphoric 
acid followed by repeated filtration and collection (Figure 2.5). The template synthesis 




Figure 2.5 Schematic representation of template synthesis of SNTs and their TEM image 
(50 nm × 200 nm) (adapted from [73]). Al2O3, aluminum oxide; Al, Aluminum; SiCl4, 















distribution, it also renders the differential functionalization of inner and outer surfaces of 
nanotubes feasible. The first functionalization is conducted to modify the inner surface of 
nanotubes before they are liberated from the template membrane (Figure 2.5). The outer 
surface is not accessible in the first round of functionalization because it is in contact 
with the template pore wall. Then, the template is dissolved to release free nanotubes; the 
outer surface is thus exposed and is available for a second functionalization. The 
differential functionalization offers multifunctionalities on nanotubes depending on their 
roles, e. g., SNTs are modified at the inner surface with drugs or imaging agents and at 
the outer surface with targeting moieties [74]. 
2.5.1.2 Bottom-up methods 
The “bottom-up” methods include the traditional ways of synthesizing SiO2 by 
substrate reaction (Figure 2.6). Nonporous SiO2 are synthesized by a Stӧber method 
developed in the 1960s and are prepared from reacting tetraethoxysilane (TEOS) in a 
mixture of ammonia, water, and ethanol [75, 76]. Nonporous SiO2 usually possesses very 
uniform size and the ammonia concentration greatly influences their size, that is, the 
higher the ammonia concentration, the larger the size of nonporous SiO2 in a certain 
range (Figure 2.6A) [77]. Mesoporous SiO2 were first synthesized by researchers in 
Mobil Company in 1992 [78]. The most extensively studied mesoporous SiO2 are the 
MCM-41 (Mobil Composite Material 41) type, which are synthesized out of the cationic 
surfactant micelle template and is characteristic of the 2D-hexagonal mesopores running 
parallel from one end to the other in the close-packed structure of the silicate product [79]. 
Possible mechanistic pathways for the formation of MCM-41 type mesoporous silicates 




Figure 2.6 Schematic illustration for the synthesis and functionalization of A) nonporous 
SiO2 (adapted from [80]), B) MCM-41 type mesoporous SiO2 (adapted from [79, 81]), 
and C) silica nanorattles (adapted from [82]) and their TEM images. NH4OH, ammonium 






that the pre-existence of surfactant association (rod-like micelles) followed by 
polymerization of silicate anions led to the formation of the MCM-41 structure; 2) 
silicate-anion initiated pathway, which suggests that the self-assembly of the liquid-
crystal-like structures results from mutual interactions between the silicate anion and the 
surfactant cations in solution [81]. In this synthesis, the shape of nanoparticles is mainly 
dependent on the CTAB concentration and the stirring rate in the reaction. The aspect 
ratio of nanoparticles could vary from 1 to 8 when CTAB concentration increases and 
stirring rate reduces. The ammonia concentration plays a crucial role in determining the 
diameter of nanoparticles, as the increase in ammonia concentration leads to the increase 
in the width of nanoparticles. Such control over synthetic conditions results in the 
production of nanoparticles with tailored geometrical features which lay the foundation 
for studying the geometry effect of nanoparticles on biological toxicity. Compared with 
the nonporous SiO2, mesoporous SiO2 have advantageous features such as large surface 
areas (600 – 1000 m2/g), uniform pore sizes, and dual-modification on inner surface or 
outer surface, making them attractive candidates as therapeutic carriers [67, 68]. 
Recently, there is an emerging synthetic pathway for generating mesoporous 
hollow silica nanospheres (MHSNs) with unique porosity and surface features based on a 
template-assisted, selective etching method (Figure 2.6C) [6]. The MHSN is of silica 
nanorattle structure by selectively etching the middle layer of organic-inorganic hybrid 
solid silica spheres (HSSSs) with hydrofluoric acid (HF). To synthesize MHSNs, the 
HSSSs with three-layer “sandwich” structure are designed in the first step with the core 
and the shell as pure silica hydrolyzed from TEOS and the middle layer as organic silica 
co-condensed from TEOS and N-[3-(trimethoxysilyl)propyl] ethylenediamine (TSD). In 
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the second step, the HSSSs are changed into silica nanorattles with an appropriate amount 
of aqueous HF, which diffuses into the middle layer of HSSSs via micropores in the shell 
and selectively etches away the middle layer. This selective-etching strategy could 
readily produce monodisperse nanorattles on a large scale with tailored size, shell 
thickness, and core diameter. By rationally choosing functional nanoparticles as core 
materials, such as gold nanoparticles, this strategy could be developed as a general tool to 
synthesize multifunctional hybrid nanorattles for a variety of applications in 
nanomedicine and catalysis [68]. 
2.5.2 Characterization 
Nanoparticle characterization is a crucial step in determining physicochemical 
properties in the relevant medium. Appropriate and systematic characterization provides 
a foundation for correlating physicochemical properties of nanoparticles with biological 
outcome and generates valid guidelines in designing nanoparticles with desirable features. 
Commonly used methods include electron microscopy and dynamic light scattering (DLS) 
measurements for size or geometry identification, X-ray diffraction (XRD) analysis for 
pore structure and ordering determination, nitrogen adsorption desorption isotherm 
analysis for surface area and pore size measurement, and other important assays before 
the samples are ready for biological evaluation (Table 2.4). 
2.5.2.1 Electron microscopy 
Transmission electron microscopy (TEM) is a standard technique to image the 
morphology and particle size distribution for micro- or nanosized solid particles. Particle 
sizing by TEM yields valid size and shape information and provides visual evidence of  
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Table 2.4 Commonly used characterization methods for SiO2 (adapted from [84]) 
Physicochemical 
properties 
Assays Function Limitation 
Size Electron 
microscopy 
Visualizes the size or shape 
at dry state  
Time consuming, 





hydrodynamic size in 
medium 










Quantifies the amount of 





Zeta potential Measures the surface 
charge in presence of 
medium 
Influence of 




Records the pore 
arrangement and 
orderliness 








Measures the surface area, 
pore size/distribution in 
samples 










Obtains the infrared 
spectrum from functional 
moieties in the sample 





Analyzes the content of 
trace elements in the 
sample 
High background 





Detects and quantifies the 











internal structure for inorganic nanoparticles via the penetrating electron beams at high 
voltage [83]. However, TEM only assesses the size of samples prepared at dry state, does 
not provide size information of nanoparticles suspended in aqueous medium, and it is 
laborious to obtain multiple TEM images from the same sample to obtain sizing 
information of statistical significance [23]. The same holds true for scanning electron 
microscopy (SEM), which gives information about the surface features and sizes of 
nanoparticles. Electron microscopy technique is usually coupled with dynamic light 
scattering analysis to generate the overall picture of nanoparticle sizing in various media. 
2.5.2.2 Zeta potential and dynamic light scattering measurement 
The physicochemical state of nanoparticles in suspension, such as surface charge 
and hydrodynamic size, is commonly identified by zeta potential or DLS measurement. 
Since nanoparticles could be exposed to various media, including water, saline, cell 
medium, serum solution, or whole blood, it is of crucial importance to identify their 
charge and hydrodynamic size in each condition as it significantly influences the 
interaction of nanoparticles with the local environment [85]. 
2.5.2.3 X-ray diffraction 
XRD is a technique in crystallography in which the patterns produced by the 
diffraction of X-rays through the closely spaced lattice of atoms in the solid state sample 
are examined [86]. The electrons that surround the atoms are the entities which physically 
interact with the incoming X-ray photons. The spacing in the lattice could be determined 
using Bragg‟s law. The pattern of diffraction peaks could be used to identify the crystal 
size, purity, and textures of the sample tested [86]. This technique is widely used in 
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chemistry or materials science to determine the structures of various crystalline 
molecules, including inorganic compounds, DNA, and proteins [87]. It is one of the basic 
characterization steps to evaluate the hexagonal pore structure and orderliness for 
mesoporous SiO2.  
2.5.2.4 Nitrogen adsorption and desorption isotherm analysis 
Nitrogen adsorption desorption isotherm analysis is used to measure the BET 
(Brunauer-Emmett-Teller ) and Langmuir surface area and BJH (Barrett, Joyner, and 
Halenda) pore size distribution of a solid sample at dry state [88, 89]. In a typical 
characterization experiment, the sample is contained in an evacuated sample tube, cooled 
to cryogenic temperature (77K), and is then exposed to analysis gas at a series of 
precisely controlled pressures. With each incremental pressure increase, the number of 
gas molecules adsorbed on the surface increases. The pressure at which adsorption 
equilibrium occurs is recorded and the changing quantity of gas adsorbed on the solid 
surface is quantified. Then, the desorption process begins in which pressure is 
systematically reduced, leading to the liberation of the adsorbed molecules. A plot of 
relative pressure vs. volume adsorbed is thus obtained by measuring the amount of 
nitrogen gas that adsorbs onto the surface and the subsequent amount that desorbs at a 
constant temperature [88]. Analysis of the isotherms provides information about the 
surface area and pore size information of the material [90]. 
2.5.2.5 Other characterization techniques 
Several techniques which address other important issues such as absence of 
contaminants are applied in nanoparticle characterization. These include: Fourier 
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Transform Infrared Spectroscopy (FTIR) used to identify an infrared spectrum of 
impurity, Inductively Coupled Plasma Mass Spectrometry (ICP-MS) used to measure the 
amount of trace element impurities from the environment, and Endotoxin detection assay 
used to detect the level of possible biological contaminants from bacteria in nanoparticle 
stocks by Limulus Amebocyte Lysate (LAL) detection assay. 
2.6 Impact of silica nanoparticle design on toxicity in biological systems 
Physicochemical properties of carriers, such as surface functionality, size, 
chemical composition, and texture, play important roles in determining the extent of 
toxicity in vitro and in vivo (Figure 2.7). However, the interdependent role of shape, pore 
size, and surface modification of the carriers on toxicity in vitro and in vivo still remains 
largely unknown. A comprehensive study that evaluates the impact of multiple 
physicochemical characteristics of SiO2 on cellular and in vivo toxicity, biodistribution, 
and pharmacokinetics is needed. 
2.6.1 In vitro evaluation 
SiO2 induced in vitro toxicity involves an incremental series of cellular responses 
that could be classified as anti-oxidant defense, pro-inflammatory effects, and 
cytotoxicity [16]. Cytotoxicity occurs at the highest level of oxidative stress, which 
means that the interference in mitochondrial inner membrane electron transfer or 
changing open/closed status of the permeability transition pore could lead to effects on 
adenosine triphosphate (ATP) synthesis and release of pro-apoptotic factors [16]. 
Common assays that reflect the extent of cytotoxicity in cell population include MTT (3-




Figure 2.7 Schematic illustration of biocompatibility of SiO2 as a function of 
physicochemical properties, such as particle size, pore size, geometry, and surface 
properties. These parameters have a complex influence on in vitro cellular uptake, 










iodine uptake, etc. [91]. The impact of nanoparticles on the cellular level could also be 
reflected by the extent of nanoparticle uptake by cells, which are quantitatively measured 
by flow cytometry analysis for fluorescently labeled nanoparticles, gamma counter for 
radiolabeled nanoparticles, and ICP-MS for metal or metallic oxide nanoparticles. 
Subcellular location and fate of nanoparticles could also indicate the potential 
interference with cellular processes and is frequently identified by phase contrast 
microscopy or TEM imaging [92], or confocal microscopy for nanoparticles with 
fluorescence capability [93]. 
2.6.2 Ex vivo evaluation 
Ex vivo analysis of nanoparticles evaluates how the effect of nanoparticle 
physicochemical parameters influences their interaction with blood constituents. The 
plasma protein binding is crucial in determining the in vivo organ biodistribution and 
clearance of nanoparticles. It has been reported that the adsorption of plasma proteins 
depends primarily on nanoparticle surface hydrophobicity or charge [94]. Nanoparticles 
whose surface is not modified, e. g., pegylated, to avoid opsonization can be cleared from 
the circulation rapidly by macrophages in the RES [94]. Hence, nanoparticle-serum 
protein interaction is generally the focus of ex vivo studies. Another common ex vivo 
assessment evaluates the interaction of nanoparticles with erythrocytes and platelets, 
which are key components involved in blood coagulation. Typical assays include 
hemolysis, platelet aggregation, or neutrophil activation studies. Understanding the 
particle structure-activity relationships at the level of interaction with cellular and protein 
components in circulation greatly facilitates the correlation of nanoparticle parameters 
with in vivo toxicity outcome. 
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2.6.3 In vivo toxicity 
The in vivo toxicity of nanoparticles is usually examined in animals by a selected 
administration route according to the arranged dosing regimen:  
1) The toxicity studies can be conducted at a single dose, which is usually within 
the therapeutic window of the drug concentration they are able to load. As long as the 
nanoparticles do not exhibit any adverse reactions at this specific dose by the end of the 
study, they are considered as safe. For example, the systemic toxicity of pegylated silica 
nanorattles at a single dose of 40 mg/kg has been evaluated and their biocompatibility 
was confirmed by histology. The drug nanocarrier was then loaded with Docetaxel (32 
wt %) and injected into animals at the same nanoparticle dose (equivalent to 20 mg/kg 
Docetaxel) to compare the toxicity and efficacy with a commercial Taxotere group (20 
mg/kg Docetaxel) [95].  
2) The toxicity studies can also be conducted at multiple doses of the same 
nanoparticles on an escalating scale. The dosing increase is stopped when adverse 
reactions are identified at the highest dose tested and a MTD is determined based on the 
absence of adverse reactions at a lower dose. Even though it might not be directly 
translated to a drug efficacy dose in preclinical settings,  the MTD could reflect the 
intrinsic toxicity level the nanoparticles impose on the biological system and can be used 
in comparison with nanoparticles of different physicochemical features, generating useful 
guidelines [96, 97]. However, there are emerging concerns since adverse reactions in 
animals eventually happen under this study design [27]. Thus, careful planning for the 




2.6.4 In vivo biodistribution and pharmacokinetics 
The tracking of nanoparticle biodistribution and pharmacokinetics is usually 
conducted in two ways, i.e., by tracing labeling agents that are covalently conjugated to 
nanoparticles (either fluorescent dyes or radioisotopes), or by measuring the elements of 
nanoparticles themselves, in this case, measuring silicon atoms from SiO2 via ICP-MS. 
There are advantages and disadvantages associated with each type of detection method. 
For tracing labeling agents, the detection is fast and simple; however, there are always 
concerns about the stability of the conjugate and whether it is tracking nanoparticles or 
the free labeling agents that are in the original stock or have become dissociated due to 
hydrolysis or enzyme cleavage [98-101]. This becomes an outstanding issue if the study 
is aimed at examining the excretion of nanoparticles into urine or feces as the breakage of 
the bond partially occurs during this process. For tracing nanoparticle elements, the 
measurement is quantitative and directly reflects the concentration of nanoparticles in 
tissues or organs. However, due to the prevalent presence of silica in the body and in the 
environment, the background noise level from the control groups is high and may 
interfere with the readings from nanoparticle samples, especially if they are not or could 
not be dosed at a high concentration [72, 102]. It has been reported that the silicon 
content in the feces and urine of the control group were very high and fluctuating since 
the mice had free access to water and commercial laboratory food [72].  This interfered 
with the calculation of excretion percentage. Careful selection for a specific detection 




2.7 Silica nanoparticles in biomedical applications and further consideration 
SiO2 offer a useful alternative to organic systems in the field of nanomedicine. 
Their intrinsic chemical stability, capacity for multifunctional modification, and low cost 
of production make them a promising candidate for such applications. Recent progress 
has enabled the production of SiO2 with distinct shape, porosity, and surface 
characteristics. To develop SiO2 as effective carriers, there are still significant challenges 
remaining and it is critical to fully analyze the effect of various physicochemical features 
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 CHAPTER 3 
IMPACT OF SILICA NANOPARTICLE DESIGN ON CELLULAR  
TOXICITY AND HEMOLYTIC ACTIVITY 
3.1 Introduction 
It has been suggested that particle shape can influence cellular uptake and toxicity 
in vitro [1-3]. For example, it has been reported that high-aspect-ratio cationic hydrogel 
particles (150 × 450 nm) were internalized by HeLa cells four times faster than 
corresponding low-aspect-ratio particles (200 × 200 nm) [1]. In addition to geometry, 
porosity and surface functionality of nanoparticles are also critical factors that can 
influence the interaction of silica nanoparticles with biological systems [4-6]. Maurer-
Jones et al. have demonstrated that 25 nm nonporous SiO2 had a greater impact on cells 
than 25 nm porous SiO2 since the former possessed higher “cell-contactable reactive 
surface area” to perturb cell function [5]. Slowing et al. have reported that the uptake of 
mesoporous silica nanoparticles by cervical cancer cells could be elevated by surface 
functionalization with cationic functionalities or targeting moiety [6]. Despite these initial 
studies, there is a need for a systematic investigation of the interdependent roles of 
nanoparticle geometrical effect, porosity, and surface functionality on cellular uptake and 
toxicity [7-9]. Such studies will enable the elucidation of predominant factors that 
determine the extent of toxicity, which will then provide practical guidance for rationally 
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designing SiO2 for biomedical applications with minimum adverse effects. 
In this chapter, multiple physicochemical parameters of SiO2 were evaluated for 
their effects on cellular toxicity and hemolytic activity. In order to compare the effect of 
pore size, mesoporous and nonporous spherical SiO2 of the same diameter (ca. 110 nm) 
were synthesized and evaluated. To demonstrate the effect of geometrical feature 
(represented as aspect ratio, ratio of length over width), silica nanorods were produced 
with similar diameters along the short axis (around 100 nm) and different lengths along 
the long axis (approximately 200 nm, 600 nm, 1,000 nm). SiO2 of different porosities and 
aspect ratios were modified with primary amine silane groups to generate cationic charge 
and compared with the anionic bare silica nanoparticles to assess the impact of surface 
charge. SiO2 with the engineered physicochemical features as mentioned above were 
subject to a series of toxicity assays on two model cell lines, namely RAW 264.7 (a 
model macrophage commonly used to represent the physiological scavengers of foreign 
nanoparticles exposed to in vivo systems [10]) and A549 (the non-small-cell lung cancer 
epithelial cells). These cells were selected as models for potential targeted delivery of 
bioactive and imaging agents. We further characterized the hemolytic activity of SiO2 as 
an initial step to evaluate ex vivo blood biocompatibility.  
3.2 Methods 
3.2.1 Synthesis of nonporous and mesoporous SiO2 
Nonporous silica nanoparticles (Stӧber) were produced using the modified Stӧber 
method [11]. 34.82 mL water, 3.25 mL ammonium hydroxide solution (29.7%), and 100 
mL ethanol were mixed and stabilized at 40 oC. 6.20 mL TEOS was added at an injection 
rate of 5 mL/min upon stirring at 550 rpm. The reaction was conducted for 1 hour and the 
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product was washed twice by ethanol and stored in ethanol. Mesoporous SiO2 of different 
shapes were synthesized through a one-step condensation under a dilute silica source and 
low surfactant concentration conditions with ammonium hydroxide solution as the base 
catalyst [12-17]. CTAB was dissolved in aqueous medium with mild heating (30 oC). 
After the solution was cooled to room temperature (22 oC), aqueous ammonia solution 
was introduced and the mixture was stirred for an hour. TEOS was added at the rate of 5 
mL/minute while the stirring continued. The mixture was further stirred for 4 hours and 
the product was autoclaved at 100 oC for 24 hours [18, 19]. Subsequently the product was 
collected by centrifugation at 15,000 rpm for 20 minutes. As-synthesized nanoparticles 
were suspended in ethanolic HCl (1.5 mL HCl in 150 mL ethanol) and heated at 60oC for 
6 hours to remove the surfactant. The complete removal of CTAB was confirmed by FT-
IR spectroscopy. 
3.2.2 Surface functionalization 
To modify the surface of SiO2 with primary amine functionalities [20], 100 mg of 
SiO2 were resuspended in 100 mL of anhydrous ethanol. (3-aminopropyl)triethoxysilane 
APTES was introduced drip by drip to SiO2 suspension upon stirring at 500 rpm under 
nitrogen flow. The mixture was stirred at room temperature for 20 hours. Amine-
modified SiO2 were collected by centrifugation and washed extensively with ethanol and 
water. SiO2 were stored in ethanol at 4






3.2.3 Nanoparticle characterization 
TEM images were taken with a Philips Tecnai microscope operating at 120 kV. 
FT-IR spectra were recorded on a Varian Cary FTIR 1000 spectrometer using KBr 
pellets. XRD patterns of SiO2 were analyzed on a Philips PANalytical X’Pert X-ray 
diffractometer (Spectris, England) using Cu Ka radiation ( = 0.1542 nm) at 45 kV and 
40 mA. The XRD spectra were recorded in the 2 range of 2-10 with a step size of 0.02o 
in a 2 scattering angle and a scanning speed of 0.01 degree/second. The slit sizes and 
specimen length were also adjusted for divergence slit, antiscattered slit, and receiving 
slit to suit for the low angle detection. Nitrogen adsorption–desorption isotherm 
measurements were completed on a Micromeritics ASAP 2010 (Norcross, GA) 
accelerated surface area analyzer at -196 oC. The SiO2 were dried at 100 
oC overnight 
before analysis. The BET-specific surface areas were calculated by using adsorption data 
at P/P0 = 0.05–0.20 [7, 9]. The external surface areas of mesoporous SiO2 were calculated 
from the t plots of their N2 adsorption isotherms [21]. Pore volume and Pore size 
distributions were obtained from adsorption branch by using the BJH method [7, 9]. 
3.2.4 Acute cytotoxicity assay 
The acute toxicity effect of SiO2 was determined by WST-8 assay on A549 cells 
or RAW 264.7 (ATCC, Manassas, VA). Cells from passages 5 through 20 were used with 
medium changing once every 3 days. A549 cells or RAW 264.7 macrophages were 
seeded at 8,000 cells/well or 16,000 cells/well in a 96-well plate in F-12k medium or 
DMEM supplemented with 10% fetal bovine serum (FBS) and maintained in a 
humidified incubator for 24 hours. SiO2 at incremental concentrations of 100, 250, or 500 
µg/mL were added to cells. Supernatants from nanoparticle stock solutions and respective 
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growth medium only were served as controls. Post-24 hours, old medium was aspirated 
and cells were washed three times with phosphate buffered saline (PBS). 100 µL 
complete medium containing 10% (v/v) Cell Counting Kit-8 (Dojindo, Rockville, MD) 
was added to each well and incubated with cells for 2 hours. The absorbance of the plate 
was recorded at 450 nm on a UV/Vis reader with a reference wavelength of 650 nm. 
3.2.5 Proliferation inhibition assay 
The cytotoxicity of SiO2 was evaluated by WST-8 viability assay on A549 cells 
or RAW264.7 macrophages. Initially, A549 or RAW cells were seeded at 2,000 
cells/well or 4,000 cells/ well in a 96-well plate and allowed settlement for 24 hours. 10, 
50, 100, 250, 500, or 1,000 g/mL of bare SiO2 or amine-modified SiO2 were added into 
the 96-well plate in triplicates. Supernatants from nanoparticle stock solutions and 
respective growth medium served as controls. Post 72 hours, old medium was aspirated 
and the following steps were the same as the procedures for acute cytotoxicity assay 
described above. 
3.2.6 Plasma membrane integrity assay 
Determination of propidium iodide uptake was used to assess the integrity of the 
plasma membrane of nanoparticle-dosed cells. A549 cells or RAW cells were seeded at 8 
× 104 cells/well or 1.6 × 105 cells/well on a 12-well plate in triplicate. After 24 hours, 
selected nanoparticles were added into each well at the concentration of 250 µg/mL. 24 
hours later, cells and medium from each well were collected into a 5 mL flow cytometry 
tube. The cell suspension was centrifuged at 1000 rpm  5 minutes, supernatant was 
decanted, and the cells were resuspended in 100 µL of PBS. 5 µL of propidium iodide 
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solution (50 µg/mL in water) was added to each tube. The tube was gently vortexed and 
incubated for 15 minutes at room temperature in the dark. 400 µL of PBS was added into 
each tube and the samples were analyzed by flow cytometry (FACScan Analyzer, Becton 
Dickinson, Franklin Lakes, NJ) within an hour. 
3.2.7 Quantitation of cellular association 
Cellular association of SiO2 was evaluated on A549 cells and RAW264.7 cells. 
A549 cells or RAW cells were seeded at 8 × 104 cells/well or 1.6 × 105 cells/well on a 
12-well plate in triplicate, 24 hours before the addition of particles. Cells were incubated 
with 100 µg/mL of SiO2 for 24 hours (37°C, 5% CO2). After cell/particle incubation, the 
old medium was aspirated and the cells were washed three times with PBS. Then the cells 
were treated with 0.5 mL of 0.1% (v/v) Triton X-100 solution in water for 15 minutes. 
After that, the cell lysate was collected into a centrifuge tube and the wells were further 
washed with 0.5 mL water. The wash was also collected into the same centrifuge tube. 
100 µL aliquots of cell lysate were used for protein content measurement by BCA assay 
(Thermo Scientific, Rockford, IL). The concentration of silicon in the cell lysate was 
measured by direct Si measurement using ICP-MS (Agilent 7500, Agilent Technologies, 
Santa Clara, CA). The amount of cellular-associated SiO2 post-1 hour incubation at 4 
oC 
or 37 oC was also measured. RAW cells were seeded at 3.2 × 105 cells/well on a 12-well 
plate in triplicate and incubated for 24 hours. After that, cells were preconditioned to 4 oC 
by incubating at 4 oC for a brief period of 10 minutes. Then silica nanoparticles were 
added to the cells at the concentration of 100 µg/mL and the cells were further incubated 
at 4 oC for another hour. Following treatment was the same as mentioned above. To make 
sure that relative cell viability in the 4 oC treated plate was not dramatically influenced by 
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exposure to cold temperature for the experimental duration, the relative viability from 4 
oC treated plate was compared with cells incubated at 37 oC for 70 minutes by WST-8 
assay. 
3.2.8 Hemolysis 
Heparin-stabilized human blood was freshly collected according to an approved 
University of Utah Institutional Review Board protocol and used within 3 hours of being 
drawn [22, 23]. 4 mL of whole blood was added to 8 mL of Dulbecco's phosphate 
buffered saline (D-PBS) and the red blood cells (RBCs) were isolated from serum by 
centrifugation at 10,016 × g for 5 minutes. The RBCs were further washed five times 
with sterile D-PBS solution. Following the last wash, the RBCs were diluted to 40 mL of 
D-PBS. 0.2 mL of the diluted RBC suspension was added to 0.8 mL of silica nanoparticle 
suspension in D-PBS at the concentrations of 12.5 µg/mL, 62.5 µg/mL, 125 µg/mL, 
312.5 µg/mL, or 625 µg/mL to make the final nanoparticle concentration at 10, 50, 100, 
250, or 500 µg/mL. All samples were prepared in triplicate and the suspension was 
briefly vortexed before leaving at static condition at room temperature for 4 hours. After 
that, the mixture was briefly vortexed again and centrifuged at 10,016 × g for 3 minutes. 
100 µL of supernatant from the sample tube was transferred to a 96-well plate. The 
absorbance value of hemoglobin at 577 nm was measured with the reference wavelength 
at 655 nm. 0.2 mL diluted RBC suspensions incubated with 0.8 mL of D-PBS and 0.8 mL 
of water were used as the negative or positive control. The percent of hemolysis was 
calculated as: Hemolysis % = [(Sample absorbance – negative control) / (positive control 




3.2.9 Statistical analysis 
The difference between multiple groups was analyzed by one-way analysis of 
variance (ANOVA); Tukey post test was used where difference was detected. For two 
group comparison, Student’s t-test was used. The difference between two groups was 
considered significant when p < 0.05. The nanoparticle concentrations that led to 10% 
hemolysis (LC10) in hemolysis assay were determined by using ED50plus v1.0 software. 
3.3 Results and discussion 
Nonporous SiO2 and mesoporous SiO2 of different geometrical features were 
synthesized and characterized using TEM, XRD, and nitrogen adsorption-desorption 
isotherm analysis for size, mesopore arrangement, surface area, and pore size 
measurement (Table 3.1). Mesoporous SiO2 of different shapes were synthesized by a 
one-step condensation and aging method [7, 12-17]. In the first step, mesoporous SiO2 
were formed by condensation under a dilute silica source and low surfactant 
concentration conditions with ammonium hydroxide as the base catalyst. The shape and 
polydispersity of SiO2 was mainly controlled by molar composition of reaction agents 
[12-16] and stirring rate [17]. By changing the concentration of TEOS, CTAB, and 
aqueous ammonia, and reaction stirring rate, mesoporous SiO2 with targeted diameters 
(ca. 100 nm), lengths, and aspect ratios (1, 2, 4, 8) were synthesized. In general, the width 
of mesoporous SiO2 was controlled by adjusting the ammonia concentration in the 
reaction mixture [7] with larger width obtained at increased ammonia concentration, 
while the length of mesoporous SiO2 increased with increased TEOS concentration, 
increased CTAB concentration, increased ammonia concentration, and reduced stirring 
speed [16, 17]. In the second step, mesoporous SiO2 were subject to autoclaving at  
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Table 3.1 Synthetic conditions of nonporous and mesoporous SiO2 and their physical 
characterization of size, surface area, and pore size.*  














Stirring rate (RPM) 550 250 230 350 250 
Temperature (
o
C) 40 22 22 22 22 
Size by TEM (nm) 115 ± 13 120 ± 25 77 ± 9 × 
198 ± 53 
159 ± 49 × 
594 ± 82 
136 ± 26 × 
1028 ± 139 
Aspect ratio 1 1 2.5 3.8 7.6 
Surface area (m
2
/g) 24 663 443 1191 284 




24 109 102 231 47 
Pore volume (cm
3
/g) N/A 0.63 0.59 1.17 0.26 
Pore size (nm) N/A 2.7 2.7 2.8 2.7 













100 oC for 24 hours to promote silica matrix crosslinking and to enhance the stability of 
mesopore structure [18, 19]. 
Evident from TEM image analysis (Figure 3.1), nonporous silica nanospheres 
(Stӧber) and mesoporous silica nanospheres (Meso S) were 115 ± 13 nm and 120 ± 25 
nm in diameter, respectively. Mesoporous silica nanorods were produced with distinctly 
different geometrical features. They possessed similar diameter as that of nanospheres 
(around 100 nm), yet the aspect ratios were different (mesoporous SiO2 with aspect ratio 
2, 4, 8 were abbreviated as AR2, AR4, and AR8, respectively). The aspect ratio 
distribution histogram showed that each type of mesoporous SiO2 possessed distinct 
shape characteristics compared with any other type of mesoporous SiO2 (Figure 3.1G), 
except that AR2 and AR4 had a certain portion of overlapped aspect ratios. However, 
they still possessed distinct geometrical features considering their dimensions were 
significantly different from each other along the short or long axes. 
Figure 3.2 presents the nitrogen adsorption-desorption isotherms for mesoporous 
SiO2 of different shapes. Mesoporous SiO2 exhibited type IV isotherms, which were 
typical of a mesopore structure. The filling of mesopores occurred at relative pressure 
(P/P0) of 0.3 to 0.5. Each type of nanoparticles also exhibited an additional capillary 
condensation at high relative pressure (P/P0 > 0.90), which was characteristic of a high 
degree of textural porosity [7, 9]. Mesoporous SiO2 possessed relatively high surface area 
(280 – 1190 m2/g), as calculated by the BET method (Table 3.1) [7, 9]. The external 
surface areas of mesoporous SiO2, which referred to cell-contactable surface area, were 
calculated from the t plots of their N2 adsorption isotherms (Table 3.1) [21]. Different 




Figure 3.1 TEM images of A) Stӧber SiO2 with average diameter of 115 nm (referred to 
as Stӧber), B) mesoporous SiO2 with average diameter of 120 nm (Meso S), C) 
mesoporous silica nanorods with aspect ratio 2 (AR2), D) mesoporous silica nanorods 
with aspect ratio 4 (AR4), E) mesoporous silica nanorods with aspect ratio 8 (AR8), and 
F) high resolution image of a single particle in B), G) The percentage distribution 








Figure 3.2 Nitrogen adsorption-desorption isotherms of: A) Meso S, B) AR2, C) AR4, 




around 2.7-2.8 nm in diameter, as determined by the BJH method (Table 3.1) [7, 9]. 
Meso S possessed typical MCM-41 type mesopore arrangement as reflected by the 
distinct peaks (100, 110, 200, 210) in XRD measurement (Figure 3.3A), which was in a 
good agreement with its high resolution TEM image (Figure 3.1F) showing 2D-
hexagonal mesopores in the close-packing structure for this type of SiO2 [16]. The 
mesopore structure of Meso S was also well maintained post-amine modification (Figure 
3.3B). Therefore, Meso S was compared with nonporous Stӧber nanoparticles to study 
the pore size effect on cellular toxicity and hemolytic activity. 
The DLS measurements showed that the Meso S tended to agglomerate to a 
higher extent (257.8 ± 0.9 nm) and was thus more polydisperse in size distribution than 
Stӧber (148.0 ± 0.4 nm) (Table 3.2). Due to the method limitations, DLS measurements 
are not applicable to mesoporous silica nanorod structure because such a measurement 
model assumes spherical shape of nanoparticles in suspension [17]. Zeta potential 
measurements showed that Stӧber nanoparticles were highly negatively charged (-50.4 ± 
1.0 mV), indicating a fairly stable suspension in aqueous medium [20]. Amine-modified 
Stӧber (SA) nanoparticles had relatively lower positive zeta potential (17.0 ± 0.7 mV), 
which implied a moderate stability in aqueous suspension (Table 3.2) [19]. Mesoporous 
SiO2 were highly negatively charged (< -30 mV) as bare nanoparticles and were all 
highly positively charged (> 30 mV) post-amine modification, which indicated a high 
stability within suspension (The amine-modified mesoporous nanospheres or nanorods 
with aspect ratio of 2, 4, 8 were abbreviated as MA, 2A, 4A, and 8A) [20]. Zeta potential 
measurements showed the dramatic surface charge difference between bare nanoparticles 




Figure 3.3 XRD patterns of A) Meso S and B) MA. Both Meso S and MA exhibited the 
typical diffraction patterns of MCM-41 type mesoporous SiO2 with hexagonal symmetry. 
The reduction in intensity of MA diffraction pattern and the missing 210 peak might be 















Table 3.2 Hydrodynamic size and surface charge of SiO2 before and after primary amine 
modification in aqueous suspension at pH 7.0.*  
 Before APTES modification Post-APTES modification 








StÖber 148.0 ± 0.4/0.043 -50.4 ± 1.0 174.2 ± 1.9/0.102 17.0 ± 0.7 
Meso S 257.8 ± 0.9/0.219 -39.4 ± 0.5 233.8 ± 2.2/0.145 32.4 ± 0.9 
AR2 N/A -33.5 ± 0.5 N/A 32.0 ± 1.0 
AR4 N/A -34.0 ± 1.2 N/A 40.3 ± 1.0 
AR8 N/A -36.6 ± 0.6 N/A 36.7 ± 0.5 
*Data were mean of average diameter/zeta potential of each measurement  ± SD (n = 1 in 













which allowed the comparative evaluation of the effect of surface characteristics on 
biological systems. However, it should be noted that the absolute value of zeta potential 
would shift in other media that were used in in vitro or in vivo analysis. Thus, the effect 
of surface characteristics in in vitro or in vivo studies was probably due to differential 
presence of surface functionalities rather than the absolute zeta potential values. The 
absence of carbon chain band (wavenumber 3000 – 2800) in the FT-IR spectrum of 
surfactant-removed nanoparticles confirmed the complete removal of CTAB from the 
products by acidic ethanol extraction method (Figure 3.4). The endpoint chromogenic 
Limulus amebocyte lysate (LAL) test (Lonza, Walkersville, MD) showed that there was 
no detectable gram negative endotoxin on any type of nanoparticles at 1 mg/mL (the 
detection limit was less than 0.1 EU/mL), which was the highest concentration of 
nanoparticles used in the in vitro and ex vivo studies. However, it must be noted that LAL 
assays could not effectively indicate the amount of endotoxin potentially adsorbed on 
nanoparticle surface [24]. Thus, the results from LAL assay showed that the level of 
soluble endotoxin in nanoparticle suspension was below the detection limit. 
The ability of SiO2 with the engineered physicochemical features to induce acute 
cellular toxicity response was tested on RAW 264.7 and A549 cells by WST-8 assay. 
Results demonstrated that toxicity of SiO2 was highly cell-type and nanoparticle-
concentration dependent (Figures 3.5-3.6). All types of SiO2 at concentration as high as 
500 µg/mL did not affect the relative viability of A549 cells after 24 hours exposure. For 
RAW 264.7 macrophages, nonporous or mesoporous SiO2 caused dramatic toxicity post- 
24 hour incubation, leaving only ca. 20-40% viable cells compared with controls, while 




Figure 3.4 Typical FT-IR spectra of A) as-synthesized mesoporous SiO2 and B) 














Figure 3.5 Acute cytotoxicity assay of indicated cells incubated with bare and amine-
modified SiO2 at 500 µg/mL. 
*** Relative viability of bare silica nanoparticle-treated cells 
was significantly lower than that of amine-modified counterpart-treated cells (p < 0.001). 














Figure 3.6 Acute cytotoxicity assay of RAW 264.7 cells after incubating with bare SiO2 











viability (Figure 3.5). Since bare SiO2 showed higher cytotoxicity on RAW 264.7, doses 
that led to reduced toxicity (250 µg/mL with ca. 70% viability) or nontoxicity (100 
µg/mL with ca. 100% viability) have been identified (Figure 3.6) to be used in the plasma 
membrane integrity assay or nanoparticle cellular association quantitation assay.  
The ability of nanoparticles to inhibit cell proliferation was cell type-dependent 
(Figures 3.7-3.10). Cancer epithelial cells were resistant to all types of nanoparticle 
treatment up to 500 µg/mL post-72-hour exposure, and only cells treated with 2A and 8A 
at 1000 µg/mL exhibited moderate toxicity response, resulting in 60-70% viable cells 
compared with controls (Figures 3.7-3.8). For macrophages, the nanoparticle 
concentration that led to 50% inhibition on cell growth (IC50) ranged approximately from 
50 to 100 µg/mL post-3-day exposure for bare SiO2 (Figure 3.9) and the IC50 of bare 
nonporous and mesoporous SiO2 were not distinguishable from one another (p > 0.05). 
Interestingly, the reduction of IC50 was not observed for nanoparticles post-amine 
modification. Instead, several-fold increase in IC50 was detected for amine-modified 
nanoparticles (Figure 3.10, Table 3.3). For example, the IC50 of AR4 and 4A were 91.6 ± 
5.9 µg/mL and 184.2 ± 17.1 µg/mL, respectively and IC50 of AR8 and 8A were 73.7 ± 
17.0 µg/mL and 224.9 ± 28.2 µg/mL, respectively. Changes in cell morphology were 
observed in RAW 264.7 post-nanoparticle exposure for 24 hours (Figure 3.11) or 72 
hours (Figure 3.12). Reduced cell density and rounded cells were observed for bare SiO2 
treated macrophages while swollen vacuoles in cells were frequently observed in amine-
modified SiO2 treated macrophages. 
To assess whether toxicity was due to soluble factors that were released from 




Figure 3.7 Proliferation inhibition assay of A549 cells after continuous 72 hours 













Figure 3.8 Proliferation inhibition assay of A549 cells after continuous 72 hours 














Figure 3.9 Proliferation inhibition assay of RAW 264.7 cells after continuous 72 hours 















Figure 3.10 Proliferation inhibition assay of RAW 264.7 cells after continuous 72 hours 













Table 3.3 Summary of IC50 values of SiO2 on RAW 264.7 macrophages.
* 
IC50 values (µg/mL) Stӧber Meso S AR2 AR4 AR8 
Bare nanoparticles# 73  3 89  4 72  12  92  6 74  18 
Amine-modified 
nanoparticles 
254 ± 15 182 ± 38 471 ± 7 184 ± 17 225 ± 28 
*Data were mean ± SD (n = 3). 
#There was no significant difference in IC50 among all types of bare SiO2 (p > 0.05), 
however, statistically significant differences were observed between IC50 of each type of 
















Figure 3.11 RAW 264.7 morphology post-24-hour incubation with:  A) cell medium, B) 
Meso S 250 µg/mL, C) MA 250 µg/mL, D) Stӧber 250 µg/mL, E) SA 250 µg/mL. 






Figure 3.12 RAW 264.7 morphology post-72-hour incubation with: A) cell medium, B) 
Meso S 250 µg/mL, C) MA 250 µg/mL, D) AR2 250 µg/mL, E) 2A 250 µg/mL, F) AR10 
250 µg/mL, G) 10A 250 µg/mL. Pictures were taken using a phase-contrast microscope 




stock aqueous suspension. Results showed that the supernatant did not affect the relative 
viability compared with controls (data not shown). To evaluate whether toxicity was due 
to adsorbed endotoxin on nanoparticles, endotoxin from reference standard E. coli stock 
was added to 500 µg/mL nanoparticle suspension to make its concentration at 0.1 
EU/mL. Results showed that the relative viability post-24-hour incubation and IC50 of 
nanoparticles post-72-hour exposure were not changed in the presence of added 
endotoxin compared with nanoparticle treatment without addition of endotoxin (data not 
shown). These results indicate that the added endotoxin did not contribute to toxicity in 
macrophages at 24 hours or 72 hours; thus, these assays did not fully explain the potential 
endotoxin-induced macrophage mortality with nanoparticle incubation. It suggests that 
the toxicity of SiO2 was due to cellular interaction with nanoparticles themselves, rather 
than a product of degradation or any associated contaminants.  
Plasma membrane damage is an important aspect of cellular toxicity upon 
nanoparticle treatment. When cells have plasma membrane damage, the propidium iodide 
in the solution passively diffuses into the cytoplasm and binds with intracellular DNA or 
RNA. By quantitating the percentage of propidium iodide positive cells, one could deduct 
the percentage of cells experiencing plasma membrane damage in the total cell 
population [26]. The results show that the ability of nanoparticles (250 µg/mL) to 
compromise the integrity of the plasma membrane after 24-hour incubation was cell type-
dependent (Figure 3.13). For cancer epithelial cells, the percentage of propidium iodide 
positive cells was less than 3% for all types of SiO2 treatment. For macrophages, Stӧber 
caused plasma membrane damage in 53% of the cell population, while all mesoporous 




Figure 3.13  Percentage of propidium iodide stained cells in RAW 264.7 cells (blue bars) 
or A549 cells (red bars) after incubating with 250 µg/mL SiO2 for 24 hours. 
***Meso S 
led to significantly decreased percentage of propidium iodide-positive cells compared 








264.7 cell population. Stӧber caused the highest percentage of propidium iodide positive 
cells, probably due to their high silanol density on the external surface that were 
accessible to the cell membrane, which caused significantly higher cellular impact than 
mesoporous SiO2 [22]. Amine-modified mesoporous SiO2 generated a higher extent of 
plasma membrane damage in ca. 38% of the cells than their bare mesoporous 
counterparts. Plasma membrane damage in cells was probably not due to the 
sedimentation of the nanoparticles, as this experiment was repeated with nanoparticles 
being added before cells were carefully plated on top of the nanoparticles and the 
observed results were very similar (Figure 3.14). Combining the results above, it seems 
that porosity and surface charge are the major factors that determine the extent of plasma 
membrane damage.  
The amount of cellular associated SiO2, which included internalized nanoparticles 
or nanoparticles adhering to the extracellular matrix, was quantitated by ICP-MS [7]. 
Results show a similar pattern of cellular association of SiO2 with macrophages and 
cancer epithelial cells. However, the amount of silicon associated with macrophages was 
10-15 times higher than that of the cancer epithelial cells (Figures 3.15-3.16). Stӧber led 
to much higher cellular association than mesoporous nanoparticles both on a particle 
mass basis and on a particle number basis (Table 3.4). The level of cellular association 
was also highest for Stӧber among all types of SiO2, including the amine-modified 
counterparts SA. This observation was possibly due to the highest silanol density on the 
continuous external surface of Stӧber, which was reflected by the highest magnitude of 
negative charge (-50 mV) for these particles [22]. The formation of porous structure or 




Figure 3.14 Percentage of propidium iodide stained cells in RAW 264.7 cells when cells 
were plated on top of SiO2 and incubated for 24 hours . 
***Meso S led to significantly less 
propidium iodide-stained cells compared with Stӧber or MA (p < 0.001). Data were mean 








Figure 3.15 ICP-MS analysis of cellular association of SiO2 in RAW 264.7 cells post-
incubation with nanoparticles at 100 µg/mL for 24 hours. ***The level of cell-associated 
silicon was significantly higher in Stӧber- or SA- treated cells than in the mesoporous 













Figure 3.16 ICP-MS analysis of cellular association of SiO2 in A549 cells post- 
incubation with nanoparticles at 100 µg/mL for 24 hours. ***The level of cell-associated 
silicon was significantly higher in Stӧber- or SA- treated cells than in the mesoporous 
counterpart-treated cells (p < 0.001). ### The level of cell-associated silicon was 
significantly higher in high aspect ratio, 8A treated cells than in MA, 2A, or 4A treated 












Table 3.4 Average cellular association of bare SiO2 detected by ICP-MS on RAW 264.7 
post-incubating with nanoparticles at 100 µg/mL for 24 hours.* 
Nanoparticle treatment Silicon content (µg)/100 µg 
protein 
No. nanoparticles/100 µg 
protein 
Stӧber 21.2 2.6 × 1011 
Meso S 0.7 1.6 × 1010 
AR2 0.8 2.2 × 1010 
AR4 0.5 1.8 × 109 
AR8 0.5 6.1 × 108 
*There was no significant difference in the amount of cellular associated silicon content 
per 100 µg protein among various types of mesoporous SiO2 (p > 0.05). Stӧber 
nanoparticles were associated with RAW 264.7 at significantly higher levels than 
mesoporous SiO2 of all types either in mass concentration or in number concentration (p 















surface of the particles (-33 mV to -39 mV for mesoporous SiO2) or shielding of surface 
silanol by amine functionalities, which reduced the accessibility of silanol groups to cells 
and in turn decreased the level of cellular association [22]. 
On the other hand, amine-modified mesoporous SiO2 (32 mV – 40 mV) showed 
significantly higher cellular association than their bare mesoprous counterparts (p < 
0.05), which appeared to contradict the aforementioned phenomenon with SA (17 mV) 
and Stӧber nanoparticles. This indicated that there could be a surface charge “threshold” 
(> 30 mV) above which the amine functionalities facilitated nanoparticle-cell interaction 
through electrostatic interaction of positively charged amine groups with negatively 
charged cell membrane, whereas below the “threshold,” there were less surface amine 
groups available and they had electrostatic interaction with surface silanols and covered 
the sites of silanol [27], which eventually reduced the level of cellular association. 
Bare mesoporous silica nanoparticles, irrespective of their shape features, 
exhibited a similar level but the lowest amount of cellular associated silicon. For A549 
cells, the level of cell-associated silicon from mesoporous SiO2 exposure was even below 
the detection limit of ICP-MS (< 0.1 µg/mL for silicon element). There was no 
significant difference in the level of cellular association among all types of mesoporous 
SiO2 (p > 0.05). There was also no significant difference in the cellular association 
among all mesoporous SiO2 post-amine modification on both cell lines (p > 0.05), except 
that 8A had significantly higher cellular association than other amine-modified 
mesoporous SiO2 on A549 cells (p < 0.001). This suggests that the curvature of cationic 
SiO2 could influence the wrapping by the cell membrane and affect the cellular 
association with non-phagocytic cells [1]. 
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In order to test if porosity, geometry, and surface modification can influence the 
cellular association at an earlier time point, selected SiO2 including Stӧber, Meso S, AR8, 
and MA were incubated with RAW 264.7 cells for 1 hour and the level of cellular 
association was detected by ICP-MS. The experiment was done at 4 oC or 37 oC to 
differentiate the amount of membrane bound SiO2 with that of internalized SiO2, as 
incubation at low temperature (4 oC) drastically reduces the energy-dependent 
internalization process in cells [28]. Considering that the viability of cells could be 
affected upon incubation at 4 oC which subsequently could influence the protein content 
recovered, the relative viability of cells post-70-minute incubation (10-minute pre-
incubation and 60-minute incubation with nanoparticles) at 4oC was measured and the 
results show that the percentage of viable cells was 94 ± 8% compared with control cells 
treated at 37 oC for the same time duration. As shown in Figure 3.17, Stӧber 
nanoparticles led to a significant increase in cellular association 24 hours post-incubation 
at 37 oC compared with 1-hour incubation at 37 oC (p < 0.001) or at 4 oC (p < 0.001), 
indicating that there was extensive internalization of nonporous nanoparticles over 24 
hours. There was no significant difference in cellular association between Meso S and 
AR8 post-1-hour incubation at 37 oC (p > 0.05). Geometry did not seem to affect the 
level of cellular associated nanoparticles for mesoporous SiO2 at the early time point as 
well. Most mesoporous SiO2 seemed to bind to the cell membrane instead of being 
internalized into the cytoplasm within an hour as the level of silicon association from 
Meso S or AR8 exposure was similar for cells incubated at 4 oC or 37 oC for 1 hour. 
However, the level of cellular association significantly increased post-incubation for 24 




Figure 3.17 Cellular association of SiO2 after RAW 264.7 cells were incubated with 100 
µg/mL selected SiO2 at 4 
oC (1 hour) and 37 oC (1 hour or 24 hours). The level of cellular 
associated silicon was significantly higher at 24 hours than at 1 hour post-incubation with 
Stӧber (***, p < 0.001), Meso S (###, p < 0.001), or AR8 (##, p < 0.01) at 37 oC.  1-hour 
incubation with Stӧber at 37 oC led to significantly higher silicon association than 










(p < 0.01), which indicated that internalization of mesoporous SiO2 had occurred. On the 
contrary, there was no significant difference in cellular association between 1-hour 
incubation and 24-hour incubation with MA at 37 oC (p > 0.05), which implied that the 
cellular association of MA almost reached the plateau within 1-hour post-incubation. The 
cellular association of MA post-1-hour incubation at 37 oC was not significantly higher 
than that at 4 oC (p > 0.05). The combined results suggest that there was limited 
internalization over 24-hour post-incubation with MA, which probably explained why 
there was a reduction in toxicity of amine-modified SiO2 compared with that of bare 
SiO2. It has been suggested that the strong association of cationic SiO2 with negatively 
charged cell membranes, which made the cationic SiO2 adhere to the cell membrane 
instead of bringing them into the cytoplasm, led to the reduction in internalization and the 
resultant decreased toxicity based on transmission electron microscopy [29-31] or 
confocal microscopy analyses [32]. Our results provide quantitative evidence by ICP-MS 
that there was limited internalization for amine-modified SiO2.  
In summary, it appears that surface charge and porosity mainly influenced the 
extent of cellular association while geometry did not seem to influence cellular 
association within the aspect ratio range of 1-8 studied. These observations are consistent 
with the experiments examining plasma membrane integrity post-nanoparticle treatment. 
The level of plasma membrane damage by nanoparticles was directly related to the extent 
of nanoparticle cellular association, which indicated a biological cause-and-effect 
relationship between cellular association and cell membrane damage to both cell lines. 
The impact of nanoparticle porosity, geometry, and surface functionality on 
human RBCs was evaluated by a hemolysis assay. The quantitation of hemoglobin in the 
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supernatant of nanoparticle-RBC mixture was done by recording the absorbance of 
hemoglobin at 577 nm with a reference wavelength of 655 nm [22, 23]. Results show that 
the extent of hemolysis was concentration-, porosity-, and geometry-dependent for bare 
SiO2 (Figure 3.18). Stӧber nanoparticles caused an immediate onset of hemolysis that 
soon reached a plateau of 17% hemolysis at ca. 250 µg/mL, probably due to its high 
negative charge which might expel RBCs (-15 mV) [33] from interacting at further 
increased nanoparticle concentration. For mesoporous SiO2 of all geometries tested, no 
hemolytic toxicity was observed below 100 µg/mL. The impact of nanoparticle geometry 
became pronounced as the concentration further increased. Mesoporous SiO2 with high 
aspect ratio demonstrated lower hemolytic activity than spherical or low aspect ratio 
mesoporous SiO2. It has been reported that the external surface area and the curvature of 
SiO2 influence their hemolytic activity by affecting the magnitude of binding energy of 
particles with RBCs or bending energy of the membrane to wrap around nanoparticles 
[27]. Large external surface area and small curvature (i.e., 1/r2 for spheres) rendered the 
hemolysis process thermodynamically favorable [27]. In this case, the external surface 
areas of Stӧber and Meso S were 24 and 109 m2/g, respectively, which agreed well with 
previous similar calculations [23, 27], and had similar curvature due to the similar size 
they possessed. However, Meso S did not lead to a higher hemolytic rate than Stӧber 
until the mass concentration exceeded beyond ca. 190 µg/mL. This indicates that there 
could possibly be a threshold in the density of silanol groups on each nanoparticle only 
above which it could cause immediate cell membrane damage upon exposure. Hence, the 
hemolytic activity depends not only on external surface area and curvature but also on 




Figure 3.18 Hemolysis assay on bare SiO2: A) Relative rate of hemolysis in human 
RBCs upon incubation with nanoparticle suspension at incremental concentrations. The 
presence of hemoglobin in the supernatant (red) was observed in: B) Stӧber suspension, 
C) Meso S suspension, D) AR2 suspension, E) AR4 suspension, and F) AR8 suspension. 
The tubes were lined in a sequence (from left to right) as negative control (PBS), positive 
control (water), 10 µg/mL suspension, 50 µg/mL suspension, 100 µg/mL suspension, 250 












The hemolytic activity of amine-modified SiO2 was surface charge- and 
concentration-dependent (Figure 3.19). As the concentration increased, there was a rapid 
onset of hemolysis for all types of nanoparticles. SA led to the lowest extent of 
hemolysis, possibly because of its lowest surface charge, whereas amine-modified 
mesoporous SiO2 caused similar rates of hemolysis. The concentrations of SiO2 leading 
to 10% hemolysis (LC10) are summarized in Table 3.5. Zhao et al. revealed that the 
affinity of SiO2 to RBCs decreased with increasing degree of surface functionality 
independent of surface charge (-43 mV – 7 mV) [27]. Results from our study as shown in 
Table 3.5 suggest that increasing the surface charge beyond a certain threshold (> 30 mV) 
might lead to an opposite effect, including enhanced interaction of nanoparticles with 
RBCs and the resultant elevated hemolysis by amine-modified mesoporous SiO2, in 
agreement with the cellular association results (Figures 3.15-3.16). It must be noted that a 
good correlation with results of different experiments is based on a similar dose (ca. ≤ 
100 µg/mL SiO2). As the dose changes beyond a certain range, the pattern from different 
experiments would shift and the correlation of various experiments at that dosage need to 
be further validated. 
3.4 Conclusion 
In summary, nonporous Stӧber silica nanospheres, mesoporous silica 
nanospheres, mesoporous silica nanorods with aspect ratio of 2, 4, and 8, as well as their 
cationic-charged counterparts were synthesized and characterized. The porosity, shape, 
and surface modification effects on cellular toxicity or hemolytic activity were evaluated 
on macrophages, cancer epithelial cells, or on human erythrocytes. The toxicity of SiO2 




Figure 3.19 Hemolysis assay on amine-modified SiO2: A) Relative rate of hemolysis in 
human RBCs upon incubation with amine-modified nanoparticle suspension at 
incremental concentrations. The presence of hemoglobin in the supernatant (red) was 
observed in: B) SA suspension, C) MA suspension, D) 2A suspension, E) 4A suspension, 
and F) 8A suspension. The tubes were lined in a sequence (from left to right) as negative 
control (PBS), positive control (water), 10 µg/mL suspension, 50 µg/mL suspension, 100 
µg/mL suspension, 250 µg/mL suspension, and 500 µg/mL suspension. Data were mean 











Table 3.5 Summary of LC10 values
 of SiO2 in human erythrocytes.
* 
LC10 values (µg/mL) Stӧber Meso S AR2 AR4 AR8 
Bare nanoparticles# 36 ± 1 154 ± 4 115 ± 1 152 ± 2 302 ± 3 
Amine-modified 
nanoparticles 
97 ± 4 30 ± 1 40 ± 1 23 ± 1 43 ± 1 
*Data were mean ± SD (n = 1 in triplicate measurements). 
#There was significant difference between the LC10 value of bare SiO2 and that of amine-
















nanoparticle treatment while the toxicity on macrophages was predominantly surface-
charge-dependent. The difference in toxicity between the two cell types could be due to 
the difference in the physiological function of each. Porosity and surface characteristics 
of the nanoparticles were the major factors that influenced the cellular association of the 
nanoparticles. Geometry did not seem to influence the extent of cellular association of the 
nanoparticles at either the early time point or over extended duration. Initial comparison 
of blood biocompatibility of nonporous and mesoporous SiO2 with varied shapes and 
surface characteristics has been demonstrated using the hemolysis assay. Bare SiO2 
showed a porosity- and geometry-dependent hemolytic activity on RBCs with 
mesoporous SiO2 at high aspect ratio exhibiting a reduced hemolytic activity.  The extent 
of hemolysis was highly zeta potential-dependent among the amine-modified SiO2 and 
results indicated that there could be a surface charge “threshold” below which the amine 
modification on SiO2 could lead to reduced hemolysis compared with their bare 
counterparts. Further studies evaluating the in vivo toxicity of SiO2 in animal models are 
needed to establish an in vitro-in vivo correlation for better prediction of toxicity in 
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INFLUENCE OF SILICA NANOPARTICLE DESIGN ON  
ACUTE TOXICITY IN VIVO 
4.1 Introduction 
The relationship between biological responses from in vitro examination and 
those from in vivo evaluation has been less well established to date [1-3]. It has been 
reported that nonfunctionalized mesoporous silicates of particle sizes 150 nm – 4000 nm, 
which induced more toxicity to mesothelial cells and myoblasts and less toxicity to 
macrophages, exhibited benign local compatibility by subcutaneous injection route, but 
with considerable systemic toxicity when administered by the intraperitoneal or 
intravenous routes in mice [1]. In Chapter 3, we evaluated the cellular uptake and toxicity 
of nonporous silica nanospheres of 115 nm in diameter, mesoporous silica nanospheres of 
similar size, and mesoporous silica nanorods with aspect ratios of 2, 4, and 8 as well as 
their cationic counterparts [4]. In vitro observations showed that the cellular toxicity of 
nanoparticles are cell-type-dependent and that surface characteristics and porosity govern 
cellular uptake rather than geometric features [4]. While in vitro observations shed light 
on the potential influence of these physicochemical characteristics on biocompatibility in 
a live biological system, a thorough investigation in animals is needed to relate the
 observed in vitro impacts of SiO2 with in vivo outcomes. 
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In this chapter, the single-dose, acute toxicity of engineered SiO2 of distinct 
shapes, porosities, and surface characteristics upon intravenous injection into immune-
competent mice is described. A series of different doses were administered to identify the 
MTD of nonporous or mesoporous silica nanospheres, mesoporous silica nanorods of 
different aspect ratios, as well as their cationic counterparts. Clinical observation, daily 
weight monitoring, hematological/blood chemistry tests, and histological examination 
were conducted to evaluate in vivo toxicity of SiO2 as a function of their physicochemical 
properties.   
4.2 Methods 
4.2.1 Nanoparticle characterization and injectable preparation 
Nonporous or mesoporous SiO2 with distinct geometrical features or drastically 
different surface characteristics were prepared as reported in Chapter 3 (Section 3.3) [4]. 
Hydrodynamic sizes of SiO2 in DI (deionized) water, physiological saline, and 50% FBS 
in saline were measured on a Malvern Zetasizer Nanoseries equipped with a back-
scattering detector (173 degrees). Various SiO2 were stored in ethanol and washed 
extensively with ethanol and DI water. SiO2 were resuspended in water or saline to make 
highly concentrated stocks. Then nanoparticles were diluted in water or saline to 1 
mg/mL at room temperature and their sizes measured by DLS. SiO2 from saline stock 
were diluted in 50% serum (prewarmed to 37 oC) to 1 mg/mL and were incubated at 37 
oC for 30 minutes followed by equilibration to room temperature (typically 5 minutes) 
before the measurements were taken [5]. To prepare SiO2 injectable formulation, the 
nanoparticles were diluted in saline to a specific concentration, vortexed and sonicated, 
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and were loaded into a 1 mL syringe under sterile conditions immediately before 
injection. 
4.2.2 Animals 
All animal experiments were performed in compliance with the University of 
Utah Institutional Animal Care and Use Committee (IACUC). Six- to eight-week-old 
female CD-1 mice were purchased from Charles River Laboratories, and housed in a 
group of five in standard cages with free access to food and water and were subject to a 
12 hour light/dark cycle. All animals were acclimated to the animal facility for at least 1 
week prior to experimental procedures. CD-1 mice have an intact immune system and 
were expected to react to nanoparticle exposure in a closer manner as in humans.  
4.2.3 MTD investigation 
Animals were received in standard cages from the animal facility with five mice 
per cage. These cages were randomly assigned to treatment groups with one cage per 
treatment and the animals in each cage were randomly numbered as M1- M5. SiO2 were 
suspended in sterile saline and injected through the tail vein in 200 µL suspension per 
mouse. Injections of sterile saline at equivalent volumes were also given to mice 
as controls for each dose phase. The starting dose administered into mice was chosen to 
be 30 mg/kg. If major adverse reactions were not observed in all five animals within 10 
days, the next dose level (100 mg/kg) was applied to a new group of mice and so forth. 
Animals that survived were euthanized by CO2 asphyxiation at the end of 10 days and the 
blood and tissues were collected. If major adverse reactions in animals were identified at 
a certain dose (toxic dose) within 10 days, a decreased dose (usually the mean value 
105 
 
between toxic dose and least tolerated dose) was used and so forth. Animals (one or 
more) may have shown the onset of major adverse reactions even before five animals in 
the same group were all injected. When this occurred, no more animals were injected and 
there were less than five animals in this treatment. Animals that showed major adverse 
reactions were immediately euthanized, and blood and tissues were collected for analysis. 
If the dose was reduced to a level that no major adverse reactions were observed in all 
five animals for 10 days, then this dose was identified as a survival dose. Histological 
evidence of organ damage and abnormal values of hematological/blood chemical indices, 
organ weight ratios, and body weight changes were also considered as evidence of major 
toxicity in mice. If such major toxicity was absent in animals from the survival dose, the 
survival dose was then considered as the MTD. Otherwise, a further decreased dose was 
selected until all major toxicities mentioned above were absent in all five animals subject 
to a specific dose, which was identified as the MTD. 
4.2.4 Hematology and blood chemistry 
Blood was withdrawn from the inferior vena cava immediately following 
euthanasia or animal death. The collected blood was stored in heparin-coated centrifuge 
tubes. The blood counts were measured within 4 hours post-collection, and plasma 
chemistry evaluated on the same day of blood collection. In the blood count analysis, 
major hematology markers from the whole blood, namely, erythrocyte count, platelet 
count, total leukocyte count, and hemoglobin level, were measured on a CBC-DIFF 
Instrument (Heska, Loveland, CO). In the blood chemistry analysis, blood samples (about 
0.3 – 0.7 mL each mouse) were briefly centrifuged at 1000 rpm for 2 minutes to obtain 
plasma. Liver function indicators (albumin, aspartate aminotransferase, alanine 
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aminotransferase, and total bilirubin), renal function indicators (blood urea nitrogen and 
creatinine), and globulin and total protein levels were tested using a DRI-CHEM (Heska, 
Loveland, CO) veterinary blood chemistry analyzer. 
4.2.5 Animal and organ weight measurements 
The animals which survived the injections of nanoparticles were weighed on a 
daily basis. Vital organs, including heart, liver, spleen, lung, and kidney were excised and 
weighed post-necropsy. The normalized weight percentages of heart, liver, spleen, lung, 
or kidney were calculated as the ratio of wet tissue weight over total body weight. 
4.2.6 Histological examination 
All the organs recovered from necropsy, including heart, liver, spleen, lung, and 
kidney, were fixed in 10% formalin in PBS solution and stored at 4 oC. The tissues were 
embedded in paraffin blocks, sliced, and placed onto glass slides. The slides were stained 
with hematoxylin and eosin (H&E). The histological examination was performed by a 
pathologist who was unaware of the treatment modalities of each animal, and images 
were taken using a light microscope (Olympus, BH-2). 
4.2.7 Calculation of dose equivalents at MTD 
The dose equivalents of nanoparticles at MTD on the basis of mass, total surface 
area, external surface area, total number, or total volume were calculated as: 
Total surface area of SiO2 at MTD (m
2/kg animals) = MTD (mg/kg) / 1000 × 
Total surface area of SiO2 (m
2/g nanoparticles). 
External surface area of SiO2 at MTD (m
2/kg animals) = MTD (mg/kg) / 1000 × 




Total number of SiO2 at MTD (nanoparticles/kg animals) = MTD (mg/kg) / 1000 
× Number of SiO2 (nanoparticles/g nanoparticles). 
Total volume of SiO2 at MTD (cm
3/kg animals) = Total number of SiO2 at MTD 
(nanoparticles/kg animals) × Volume of a nanoparticle (cm3/nanoparticle) 
4.2.8 Statistical analysis 
Multigroup comparisons of the means were carried out by one-way ANOVA test 
using Graphpad Prism. Statistical significance for all tests was set at p < 0.05. Results are 
expressed as mean ± SD (n = 3-5). 
4.3 Results 
Stӧber, Meso S, AR2, and AR8 were previously synthesized and stored in 
ethanol. The pristine SiO2 of various types were further modified with APTES to obtain 
their highly cationic counterparts (SA, MA, 2A and 8A). The overall physicochemical 
features of various SiO2 are summarized in Figure 3.1 and Tables 3.1-3.2 in Chapter 3 
[4]. The hydrodynamic sizes of selective spherical SiO2 (Stӧber, Meso S, MA) in DI 
water, physiological saline, and 50% serum were assessed by dynamic light scattering 
(DLS) to analyze the effect of porosity or surface characteristics on nanoparticle 
dispersive status in media. Results showed that SiO2 had good dispersivity in water or 
saline except that MA exhibited some degree of agglomeration in saline (Table 4.1), 
probably due to decreased electrostatic repulsion in the salt solution and enhanced 
interaction of surface amine with salinol groups on nanoparticles [6]. When incubated in 
50% serum at 37 oC for 30 minutes, Meso S exhibited significantly higher hydrodynamic 
size than in water or saline (p < 0.001)(Table 4.1). This indicates that protein molecules  
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Table 4.1 Hydrodynamic sizes of selective spherical SiO2 in DI water, physiological 
saline, and 50% serum at 1 mg/mLa 
 
Nanoparticle Size in DI water 
(nm)/PDI 
Size in saline 
(nm)/PDI 
Size in 50% serum 
(nm)/PDI 
Stӧber 170.3 ± 0.8/0.059 139.6 ± 0.2/0.053 121.6 ± 1.6/0.053 
Meso S 208.6 ± 1.2/0.145 200.6 ± 1.5/0.137 268.9 ± 6.3***/0.166 
MA 206.0 ± 0.5/0.140   855.7 ± 2.8/0.498 150.3 ± 0.6###/0.102 
aData are mean of average diameter of each measurement ± SD (n = 1 in triplicate 
measurements). ***The hydrodynamic size of Meso S was significantly higher than that of 
Stӧber in 50% serum (p < 0.001). ###The hydrodynamic size of MA was significantly 
















adhered to the surface of Meso S and suggests the formation of a “nanoparticle-protein 
corona” upon incubation with proteins [6, 7]. The hydrodynamic sizes of Stӧber or MA in 
50% serum were significantly lower than their sizes in water or saline (p < 0.001) (Table 
4.1). This implied that there was limited nanoparticle association in water or saline and 
addition of protein molecules served as the dispersion stabilizer and resulted in a decrease 
in average diameter of nanoparticles [8, 9]. In this case, the protein molecules were 
probably adsorbed onto the nanoparticle surface and provided steric hinderance that 
potentially prevented nanoparticles from agglomorating [8, 9]. To compare the 
hydrodynamic sizes of SiO2 in 50% serum across the board, Meso S had significantly 
higher size than Stӧber (p < 0.001), while MA possessed significantly lower size than 
Meso S in 50% serum (p < 0.001) (Table 4.1).  
MTD is defined as the highest dose that does not cause major adverse reactions in 
mice over 10 days post-intravenous injection [10, 11]. Major adverse reactions are 
considered to be immediate death, impaired mobility or irregular breathing that could not 
be recovered within a day, or over 10% weight loss over continuous days, or histological 
evidence of organ toxicity. In this study, toxic dose(s) were first reached as major adverse 
reactions were observed in a test group of five mice (named as M1 – M5) at that specific 
dose. Then the dose was reduced to a level identified later as MTD based on summarized 
clinical, hematological, blood chemical, and histological examinations. Nanoparticle 
treatments administered to mice are expressed as “nanoparticle type (,) dose (mg/kg)” 
throughout the chapter. The overall dosing procedure and animal response is summarized 
in Figure 4.1. The detailed record of animal adverse reactions from SiO2 dosing is shown 




Figure 4.1 Summary of the experimental procedures and outcomes of MTD investigation 






Table 4.2 Mortality rate of CD-1 mice post-intravenous injection of SiO2 at various doses 
and the time to reach life termination for each animal which showed major adverse 
reactions (animal identity shown). 
Treatment Dose 
(mg/kg) 
Mortality Time to death post injection 
Stӧber 600 1/5 Died 2 days later (M3) 
Meso S 100 1/5 Died at 27 hours (M2) 
 65 1/5 Died at 20 hours (M2) 
 50 1/5 Died at 24 hours (M4) 
AR2
a
 100 3/5 Died at 24 hours (M4), Died 2 days 
later (M1, M5) 
AR8 100 2/5 Sacrificed at 24 hours (M5), died 2 
days later (M2) 
SA 600 1/5 Died 3 days later (M3) 
MA 300 2/2 Died immediately (M4), euthanized at 
22 hours (M2) 
 200 1/2 Died immediately (M1) 
2A 200 3/5 Died 1 day later (M4) or 2 days later 
(M1, M5) 
 150 1/4 Euthanized immediately (M5) 
8A 300 1/1 Died immediately (M1) 
 200 1/1 Died immediately (M1) 
 150 1/1 Died immediately (M3) 
aAR2 causes kidney injury in one animal (M1) as shown in histological evaluation at the 
dose of 65 mg/kg, which is then considered as a toxic dose even when it does not lead to 










The MTDs of various types of nanoparticles are summarized in Table 4.3. As 
shown, the MTDs of nonporous SiO2, either bare or amine-modified, were the highest 
(450 mg/kg) among all types of SiO2 studied. Mesoporous SiO2 had a remarkably low 
safety threshold with MTDs between 30 mg/kg to 65 mg/kg, irrespective of geometrical 
features. Any higher doses could cause major adverse reaction, which was reported by 
previous studies that animals had immediate death post-intravenous injection of 
mesoporous SiO2 at 6 mg/mouse (approximately 240 mg/kg) [1]. Toxicity was alleviated 
by modifying mesoporous SiO2 with primary amine groups, resulting in a 2-3-fold 
increase in MTDs to 100 – 150 mg/kg. For the animals which survived treatment, they 
showed normal weight gain 10 days post-injection (Figure 4.2) and there was no clinical 
difference in organ weight percentages between treatment groups and the control group 
(Figure 4.3).  
In order to gain comprehensive understanding about nanoparticle impact in vivo, 
blood was collected after animal termination for the diagnosis of SiO2 toxicity. Major 
hematology markers from the whole blood, including erythrocyte count, platelet count, 
total leukocyte count, and hemoglobin level, were measured in complete blood count 
analysis. Kidney and liver functions were evaluated in the blood chemistry analysis. 
Renal function was examined by blood urea nitrogen and creatinine concentrations, while 
liver function was tested through plasma levels of albumin, aspartate aminotransferase, 
alanine aminotransferase, and total bilirubin. Globulin level was measured as a potential 
indicator of an immune reaction as the increase in both total leukocyte count and globulin 
concentration reflected the onset of inflammation. Animals that survived showed no 
significant changes  in blood counts or blood biochemical indices between SiO2 treatment 
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Table 4.3 MTDs of SiO2 with engineered physicochemical characteristics and the major 







Main adverse reaction(s) above 
MTD 
Stӧber 450 Heart, lung, spleen Thrombosis on endocardium 
 or in lung, anemia 
Meso S 30 Kidney Renal congestion 
AR2 30 Kidney Renal congestion 
AR8 65 Kidney Renal congestion 
SA 450 Lung, kidney Pulmonary and renal congestion 
MA 150 Lung, kidney Pulmonary and renal congestion 
2A 100 Lung, kidney Pulmonary and renal congestion 



















Figure 4.2 Normalized weight changes over 10 days post-intravenous injection of 
various SiO2 at indicated doses. No significant difference in normalized weight gain was 
observed between treatment groups and the control group for each injection phase (four 








Figure 4.3 Organ weight percentage analysis of A, F, K, P) heart; B, G, L, Q) liver; C, H, 
M, R) spleen; D, I, N, S) lung; E, J, O, T) kidney from the survived animals subject to 














groups at all doses tested and the control groups (p > 0.05) (Figures 4.4-4.7), except that 
animals that survived from AR8 100 mg/kg showed significantly higher total bilirubin 
concentration than controls (p < 0.05) (Figure 4.5I), or animals dosed with Stӧber at 600 
mg/kg had significantly lower hemoglobin level (p < 0.001) (Figure 4.7D) coupled with 
significantly higher alanine aminotransferase concentration than controls (p < 0.001) 
(Figure 4.7H). Stӧber caused hematological toxicity or hepatocellular injury at the high 
dose of 600 mg/kg. All surviving animals from the entire study had less than 0.2 mg/dL 
creatinine level upon euthanasia, indicating normal kidney function.  
Among animals showing adverse reactions, renal compromise was the major 
abnormality of animals treated with mesoporous SiO2 (Meso S, AR8) or MA, as 
indicated by dramatically increased blood urea nitrogen level (> 140 mg/dL versus 18 ± 3 
mg/dL in control) or creatinine concentration (2 - 2.4 mg/dL versus < 0.2 mg/dL in 
control) (Table 4.4). Coupled with increased kidney weight percentages (0.99% - 1.19% 
versus 0.66 ± 0.01% in control), these data suggest that the kidney was the target organ of 
mesoporous SiO2 intravenous toxicity, irrespective of geometrical features or surface 
characteristics (Table 4.4). There was an increase in liver weight percentage across the 
board for mesoporous SiO2 treatments (5.75% - 6.37% versus 4.41 ± 0.19% in control) 
(Table 4.4). Combining the significantly increased total bilirubin concentrations in 
animals from AR8 100 mg/kg (p < 0.05) (Figure 4.5I), it seems that liver function was 
affected by exposure to mesoporous SiO2. No inflammatory responses were observed in 
the animals showing acute toxicity as the total leukocyte counts remained in the normal 
range (Table 4.4).  




Figure 4.4 Blood counts (A-D) and blood chemistry (E-K) of animals treated at the dose 
of 30 mg/kg. No significant difference was observed in the hematological or chemical 
indices between various SiO2 treatment groups and the control (p > 0.05). There were 
individual animals (Meso S 30 M1 or 8A 30 M2) which exhibited elevated aspartate 





Figure 4.5 Blood counts (A-D) and blood chemistry (E-K) of animals treated at the dose 
of 100 mg/kg. Only the surviving animals from AR8 100 mg/kg exhibited a significant 
increase in total bilirubin concentration compared with the control (*p < 0.05). There 
were individual animals (Meso S 100 M4, M5 or SA 100 M2) which exhibited elevated 





Figure 4.6 Blood counts (A-D) and blood chemistry (E-K) of animals treated at indicated 
dose. No significant changes were observed between each SiO2 treatment group and the 
control (p > 0.05). There were individual animals (AR2 65 M1 or SA 300 M1) which 
exhibited elevated aspartate aminotransferase or alanine aminotransferase levels (value 




Figure 4.7 Blood counts (A-D) and blood chemistry (E-K) of animals treated at indicated 
dose. No significant changes were observed between each SiO2 treatment group and the 
control, except that the surviving animals from Stӧber 600 mg/kg showed significant 
decrease in hemoglobin concentration (***p < 0.001) and significant increase in alanine 
aminotransferase level (***p < 0.001) compared with the control.  
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Table 4.4 Hematological and blood chemical indices of selected mice which exhibited 
major adverse reactions post-intravenous injection of SiO2 at toxic doses and the organ 
weight percentages and weight changes upon necropsy of each mouse 
Treatment Saline* Meso S AR2 AR8 MA 








Complete blood count      
Erythrocyte count (106/µL) 8.62 ± 0.18 7.25 5.34 8.51 8.00 
Platelet count (103/µL) 257  ± 123 163 139 262 319 
Total leukocyte count (103/µL) 5.7 ± 2.8 2 1.9 3.1 2.7 
Hemoglobin (g/dL) 15.1  ± 0.4 13.9 15.9 15.6 14.1 
Blood chemistry      
Kidney function 
Blood urea nitrogen (mg/dL) 18 ± 3 >140 n/a >140 >140 
Creatinine (mg/dL) <0.2 2.4 n/a 2 2.2 
Liver function 
Albumin (g/dL) 2.2 ± 0.4 1.3 n/a 1.5 2.2 
Aspartate aminotransferase (U/L) 179 ± 138 243 n/a 162 334 
Alanine aminotransferase (U/L) 32 ±  5 23 n/a 20 129 
Total bilirubin (mg/dL) 0.8 ± 0.3 1.1 n/a 1.3 1.8 
Other biomarkers 
Globulin (g/dL) 2.3 ± 0.2 4.1 n/a 3.6 3.3 
Total protein (g/dL) 4.5 ± 0.4 5.4 n/a 5.1 5.5 
% Body weight      
Heart 0.49 ± 0.05 0.43 0.59 0.44 0.44 
Liver 4.41 ± 0.19 5.94 6.37 5.75 4.70 
Spleen 0.32 ± 0.04 0.28 0.34 0.36 0.26 
Lung 0.81 ± 0.06 0.55 0.99 1.04 0.83 
Kidney 0.66  ± 0.01 0.99 1.06 1.19 1.13 
% Normalized weight  upon 
death 
3.50 ± 2.44 -8.52 -4.43 -4.18 -4.16 









major organs from animals were subject to histological evaluation. Compared with 
control animals that received saline (Figure 4.8), the animals treated with nonporous SiO2 
(Stӧber) at a high dose of 600 mg/kg developed thrombosis on the endocardium of the 
heart (Figures 4.9A, 4.10A). Extensive lung hemorrhage was also observed (Figure 
4.9D). The presence of macrophages with light bluish grey cytoplasm suggests that SiO2 
uptake was detected in the spleen and liver (Figure 4.10B-C). Since animals of this group 
also showed significantly increased alanine aminotransferase level in the plasma (p < 
0.001) (Figure 4.7H), it could be deducted that these animals experienced moderate liver 
dysfunction. This may be induced by nanoparticle accumulation or by the secondary 
effect of obstructive damage to the circulatory and respiratory systems (mainly heart and 
lung) by Stӧber. 
Mesoporous SiO2, irrespective of the geometrical features, caused vascular 
congestion in viscera of mice at the dose of 100 mg/kg (Figures 4.11-4.15), especially in 
the medullary interstitium of the kidney (Figures 4.11F, 4.13F, 4.14F). This change 
corresponded with elevated levels of renal biomarkers from these animals (Table 4.4). It 
could be due to compromised blood flow in the vasa recta which makes the renal 
interstitium a likely location for thrombosis [2]. Calcium deposition was observed as 
intense blue staining in the cortex in one animal (M1) from AR2 65 mg/kg treatment 
(Figure 4.16). This indicates that kidney damage occurred; therefore, 65 mg/kg was ruled 
out as MTD and the lower dose of 30 mg/kg was determined to be MTD for AR2. No 
histological abnormality was found in major organs of the animal (M1) from Meso S 30 
mg/kg treatment (Figure 4.17) and thus, 30 mg/kg was still considered as the MTD for 




Figure 4.8 Light microscopic analysis of organs recovered from control group: A) heart, 
B) liver, C) spleen, D) lung, E) kidney (glomeruli), F) kidney (tubules). All H&E staining 











Figure 4.9 Light microscopic analysis of organs recovered from Stӧber 600 mg/kg M2: 
A) heart (40×), rectangle box indicates the area that is amplified and shown in G, B) 
liver, C) spleen, D) lung, arrows indicate hemorrhage into the alveoli, E) kidney 
(glomeruli), F) kidney (tubules), G) heart. The arrow indicates fibrosis layer organized 
around the thrombus. All H&E staining images were 200× the original magnification 









Figure 4.10 Light microscopic analysis of organs recovered from Stӧber 600 mg/kg M3: 
A) heart (thrombus body shown), B) liver, arrow indicates macrophage with light grey 
cytoplasm suggesting SiO2 presence, C) spleen, arrows indicate macrophages with light 
grey cytoplasm implying SiO2 presence, D) lung, arrows indicate congestion in the 
pulmonary capillary, E) kidney (glomeruli), arrow indicates congestion in the interstitium, 













Figure 4.11 Light microscopic analysis of organs recovered from Meso S 100 mg/kg M2: 
A) heart, arrow indicates the congestion in the capillary, B) liver, C) spleen, D) lung, E) 
kidney (glomeruli), F) kidney (tubules), arrows indicate vasa recta congestion. All H&E 
















Figure 4.12 Light microscopic analysis of organs recovered from Meso S 100 mg/kg M5: 
A) heart, B) liver, C) spleen, D) lung, arrow indicates lung edema, E) kidney (glomeruli), 



















Figure 4.13 Light microscopic analysis of organs recovered from AR2 100 mg/kg M4: 
A) heart, B) liver, arrows indicate congestion in hepatic capillaries, C) spleen, D) lung, 
arrow indicates the hemorrhage in the alveoli, E) kidney (glomeruli), F) kidney (tubules), 
arrows indicate congestion in the renal interstitium. All H&E staining images were 200× 


















Figure 4.14 Light microscopic analysis of organs recovered from AR8 100 mg/kg M5: 
A) heart, B) liver, C) spleen, D) lung, arrow indicates lung edema, E) kidney (glomeruli), 
circle indicates the tubule that went through degeneration with protein seen in the tubule, 
arrow indicates congestion in the glomerulus, F) kidney (tubules), circle indicates the 
degeneration in the tubule with protein seen in the tubule, arrows point to the congestion 
















Figure 4.15 Light microscopic analysis of organs recovered from AR8 100 mg/kg M3: A) 
heart, B) liver, C) spleen, D) lung, circle encloses the hemorrhage in the alveoli, E) 
kidney (glomeruli), arrows indicate contracted glomeruli with fibrosis observed in the 
cortex, F) kidney (tubules), arrows indicate fibrosis formation in the medulla. All H&E 













Figure 4.16 Light microscopic analysis of organs recovered from AR2 65 mg/kg M1: A) 
heart, B) liver, C) spleen, D) lung, E) kidney (glomeruli), arrows indicate calcium 










Figure 4.17 Light microscopic analysis of organs recovered from Meso S 30 mg/kg M1: 
A) heart, B) liver, C) spleen, D) lung, E) kidney (glomeruli), F) kidney (tubules). All 












Amine-modified nonporous or mesoporous SiO2 caused hemorrhage or 
congestion in the lung and kidney (Figures 4.18-4.21). Pulmonary embolism was 
observed in the lung in animal M2 from MA 300 mg/kg which was sacrificed 22 hours 
post-injection due to acute adverse reactions (Figure 4.19G). The histological 
examination confirmed the onset of lung thrombosis with renal congestion (Figure 4.19D, 
F).  One mouse (M1) from 8A 300 mg/kg died immediately post-injection and pulmonary 
embolism was observed upon necropsy with confirmation by histologic observation of 
pulmonary congestion with additional symptoms of kidney congestion (Figure 4.21). The 
presence of macrophages with light bluish grey cytoplasm in the liver or spleen indicated 
the association of amine-modified SiO2 with RES in these organs (Figures 4.18-4.19). In 
the animals treated with amine-modified SiO2 at high doses, the color of red pulp in the 
spleen turned from pinkish red to light blue, probably because of the extensive 
association of amine-modified SiO2 with macrophages (Figures 4.18C, 4.19C). 
In sum, histological examination demonstrated that there was minimum cellular 
toxicity that occurred in major organs (heart, liver, spleen, lung, and kidney). Lesions 
were mainly associated with mechanical obstruction in the vasculature upon intravenous 
injection of various SiO2 which resulted in congestion in major organs and consequently 
led to organ failure and life termination. At the MTD or even lower doses of each type of 
nanoparticle, no pathologic changes were found in major organs of SiO2 treatment groups 
compared with control groups, including individual animals (8A 30 mg/kg M2, SA100 
mg/kg M2, SA 300 mg/kg M1) which showed moderate liver enzyme level increase in 
plasma (Figures 4.4-4.6G-H). The major adverse reactions to intravenous injection of 




Figure 4.18  Light microscopic analysis of organs recovered from SA 600 mg/kg M3: A) 
heart, the circle refers to hemorrhage into the cardiac muscle, the arrow on top indicates 
the hemorrhage that separates the cardiac fiber, the arrow below indicates the cardiac 
fiber surrounded by the hemorrhage, B) liver, C) spleen, arrows in B and C indicate 
macrophages with light bluish grey cytoplasm implying SiO2 internalization, D) lung, 
arrows indicate bluish grey congestion in the capillary suggesting SiO2 presence  and the 
circle encloses the hemorrhage in alveoli, E) kidney (glomeruli), arrows indicate 
congestion in the glomeruli, F) kidney (tubules), arrows indicate hemorrhage into renal 








Figure 4.19 Light microscopic analysis of organs recovered from MA 300 mg/kg M2: A) 
heart, B) liver, C) spleen, arrows point to macrophages with light bluish grey cytoplasm 
indicating SiO2 uptake, D) lung, the arrow indicates congestion in the capillary, E) kidney 
(glomeruli), F) kidney (tubules), arrows indicate intravasculature congestion. G) 
Pulmonary embolism (pointed by the arrow) was observed upon necropsy of this animal.  













Figure 4.20 Light microscopic analysis of organs recovered from 2A 200 mg/kg M4: A) 
heart, B) liver, C) spleen, D) lung, arrow indicates the hemorrhage in the alveoli, E) 
kidney (glomeruli), F) kidney (tubules), arrows indicate congestion in the renal 


















Figure 4.21 Light microscopic analysis of organs recovered from 8A 300 mg/kg M1: A) 
heart, arrow indicates hemorrhage into the cardiac muscle, B) liver, C) spleen, D) lung, 
arrows indicate pulmonary congestion, E) kidney (glomeruli), F) kidney (tubules), arrows 
indicate congestion in the renal interstitium. G) Pulmonary embolism was observed upon 









Table 4.5 lists the dose equivalents of nanoparticles calculated on the basis of 
mass, total surface area, external surface area, total nanoparticle number, or total 
nanoparticle volume normalized to the animal weight [4]. It can be observed that dosing 
based on a total surface area was the most relevant parameter in evaluating the MTD of 
nanoparticles administered by the intravenous route since the variation of MTD 
equivalent dose expressed as total surface area per kilogram was the lowest (27%) among 
the five dose equivalents. This agreed well with previous studies, indicating that similar 
gene expression changes in cell culture [12] or similar toxicity thresholds to liver in mice 
[13] were achieved for nonporous SiO2 of different sizes dosed on an equivalent surface 
area basis. In our case, reaching MTD, as the common biological outcome, has been 
achieved for SiO2 of different porosities or geometrical features that were dosed on an 
equivalent total surface area basis of 15.6 ± 4.3 m2/kg animals. 
4.4 Discussion 
Toxicity profile of SiO2 is a crucial factor in determining their potential 
application in nanomedicine. In this chapter, we investigated the single-dose, acute 
toxicity of engineered SiO2 of various shapes, porosities, and surface characteristics upon 
intravenous injection to immune-competent mice. In order to explain the difference in 
MTD and to relate it with SiO2 physicochemical properties, representative spherical SiO2 
were incubated with 50% serum at 1 mg/mL for 30 minutes at 37 oC to evaluate the 
hydrodynamic size changes by DLS measurement. 50% serum was used to mimic the in 
vivo protein environment when nanoparticles were exposed to the circulation. SiO2 
concentration 1mg/mL was equivalent to initial blood concentration achieved at 100 
mg/kg dose, which led to a drastic difference in animal response to intravenous injection 
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Table 4.5 The dose equivalents of nanoparticles at MTD on the basis of mass, total 
























Stӧber 450 10.8 10.8 25.6 20.5 
Meso S 30 19.9 3.2 3.0 3.3 
AR2 30 13.3 3.0 4.2 3.2 
AR8 65 18.4 3.0 0.4 4.7 
AVG 143 15.6 5.0 8.3 7.9 
ST 204 4.3 3.8 11.6 8.4 
















of various SiO2. Since SiO2 exhibited a relatively fast blood clearance and majority of 
SiO2 were removed from circulation in several minutes, incubation time of SiO2 in serum 
was chosen at 30 minutes to reflect the time length most SiO2 interacted with serum 
protein before they were taken up by the RES system. Stӧber exhibited the smallest 
hydrodynamic size post serum incubation, which was related to highest MTD in vivo 
among all SiO2 tested. Meso S showed the largest hydrodynamic size post protein 
exposure. This could explain that it easily caused vasculature congestion in major organs 
at a low dose, as confirmed by histological examination, leading to the lowest MTD. The 
cationic MA, amine-modified counterpart of Meso S, had significantly lower 
hydrodynamic size than Meso S (p < 0.001), leading to onset of vessel congestion only at 
higher dose and several folds increase in MTD. It should be noted that slight 
agglomeration of MA was observed in saline. However, the agglomerates were 
dissociated when MA from the same saline stock was diluted in 50% serum, probably 
due to steric stabilization by protein adsorption. Nevertheless, injecting MA in saline 
might lead to congestion in vasculature because of lack of protein stabilization, especially 
at higher doses of MA. This could possibly explain why the MTD of MA was several 
folds lower than that of Stӧber, even when their sizes in protein solution were similar. 
Overall porosity and surface characteristics of SiO2 were the major factors that 
determined hydrodynamic size change post-protein adsorption, the related vasculature 
impact, and in vivo tolerance threshold. 
Differential patterns of toxicity in major organs were observed in animals, 
probably due to varied physicochemical characteristics of SiO2 combined with 
physiological traits of different organs. When administered through the tail vein, 
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nanoparticles were rushing through the inferior vena cava to the heart, resulting in 
damage to the endocardium of the heart leading to a series of cardiovascular 
complications [14], such as thrombosis as found in nonporous Stӧber treated animals at 
high dose. The lung is the following organ which receives 100% cardiac venous output 
and serves as a first-pass filter capillary bed for foreign bodies [15]. Any aggregation of 
nanoparticles formed in the blood can then cause obstruction in the capillaries of the 
lung, resulting in acute embolism [15]. Injection of MA, 2A, and 8A at high doses often 
led to acute death in animals in such a manner. After traversing the lung, the oxygenated 
blood with SiO2 returned to the heart and was distributed to the whole body. In this 
process, the kidney is likely the most vulnerable organ to SiO2 exposure among five 
major organs examined, probably because of its specialized vasculature organization. As 
a selective blood filter, the kidney receives 20% of the cardiac output and compromising 
the blood flow in the vasa recta in renal interstitium will lead to congestion upon 
exposure to mesoporous SiO2, which showed larger hydrodynamic size in the presence of 
protein or amine-modified SiO2. The renal congestion leads to onset of renal failure, a 
consequence which was observed in mesoporous SiO2 or amine-modified SiO2 treated 
mice. Liver and spleen were the major sites where the majority of SiO2 eventually was 
collected regardless of variation in physicochemical properties because of the abundant 
blood supply and the major presence of RES in these organs [3, 16]. It must be noted that 
animals from Stӧber 600 mg/kg treatment experienced splenomegaly (Figure 4.3R) and 
anemia (Figure 4.7D) simultaneously. Histological examination revealed that this 
concurrence could be due to infiltration and hyperplasia of macrophages in the spleen 
(Figure 4.10C).  The macrophage hyperactivity could be linked to anemia through one or 
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more of the following mechanisms: a) displacement of the hematopoietic centers in the 
spleen results in less erythrocyte production, b) physical spleen enlargement entraps more 
erythrocytes as the blood passes through the spleen, c) SiO2 engulfment by splenic 
macrophages could result in hyperactivity in phagocytosis from macrophages at all 
locations of spleen, or d) a combination of two or more mechanisms mentioned above. 
Thus, SiO2 exposure could lead to hepatic or splenic toxicity at high dose. In all, results 
set caution for developing SiO2 as a functional carrier in a drug or biological delivery 
system, especially for nonporous SiO2 as a heart disease targeted system [17] or for 
mesoporous SiO2 as an intravascular delivery system [18]. Understanding how variations 
in multiple critical physicochemical factors influence toxicity helps establish guidelines 
for selecting appropriate compositions and properties of SiO2 to improve biocompatibility 
and maximize its potential utility in nanomedicine applications. 
Since most of the nanoparticle toxicity found in this study was related to 
vasculature damage, it was expected that toxicity could also be due to interaction of 
nanoparticles with the endothelium that lines the entire circulatory system. It was 
reported that nonporous SiO2 caused toxicity in the primary endothelial cell culture in 24 
hours at concentrations higher than 100 µg/mL [19]. Interaction of nanoparticles with 
macrophages could also play an important role in affecting the organ toxicity level, as 
reflected in previous studies that demonstrated that inhibition of phagocytosis of Kupffer 
cells elevated the liver injury by 70 nm nonporous SiO2 [20]. Our previous study showed 
that there was a concentration threshold of safety for SiO2 of various physicochemical 
properties on macrophages such that above the concentration of 100 µg/mL, SiO2 tended 
to cause cellular toxicity in macrophages post-24-hour incubation [4]. In this study, 
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assuming the density of animal tissue is equivalent to water (1 g/cm3) [21], the 
nanoparticle dose mg/kg could be converted to mg/1000 cm3 or µg/mL to relate the in 
vivo results with in vitro observations. In this case, at the tested toxic dose of Meso S, 
AR2, and AR8 (i.e., 100 mg/kg), toxicity was most likely due to vasculature obstruction 
since toxicity on endothelial cells or macrophages should be limited at this concentration 
within the time frame (1 day) in animals. For amine-modified mesoporous nanoparticles 
(MTDs 100 -150 mg/kg), the toxicity that was immediately observed at the doses above 
MTDs was basically because of pulmonary obstruction by clinical observation, while the 
toxicity that was found in animals at extended time points (1 day or more) could be 
partially derived from endothelium or macrophage dysfunction due to nanoparticle 
exposure above 100 µg/mL. For Stӧber or SA, the toxicity at the dose (600 mg/kg) above 
MTDs could possibly be due to vasculature compromise as well as endothelial cell and 
macrophage toxicity (600 µg/mL). Liu et al. reported that nonporous SiO2 given through 
the intravenous route were associated with increased risk of cardiovascular diseases, i.e., 
atherosclerosis and thrombosis, by inducing endothelial cell dysfunction through 
oxidative stress via JNK/p53 pathways [19]. Our result supports this prediction that SiO2 
lead to the onset of vascular diseases besides other organ toxicities in vivo. 
Surface area of engineered particles has been shown to play a crucial role in 
determining their biological activity [22, 23]. For nanosized particles, the increased 
surface area per mass compared with large particles could induce greater biological 
interaction, which could be either desirable (e.g., loading capacity of therapeutics) or 
detrimental (e.g., toxicity, cell dysfunction) [22, 23]. Our study revealed that given the 
same surface characteristics and bulk chemical composition, the total surface area of SiO2 
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per mass is the most relevant factor that determines the MTD of SiO2 in animals. The 
MTD of Stӧber was surprisingly close to the maximum safety dose (500 mg/kg) of the 
mesoporous hollow silica nanoparticles (MHSNs, ca. 110 nm in diameter), as determined 
in previous dose escalation studies [24]. MHSNs were produced by a modified Stӧber 
method and the surface of MHSNs should resemble Stӧber used in our study, except that 
irregular pores were present on the surface with amine groups extending out from the 
inner cavity to produce a high cationic charge [25]. Although MHSNs possessed higher 
surface area per mass, they still had a high MTD which could probably be due to the 
different surface characteristics mentioned above. This indicates that porosity and surface 
characteristics are the crucial factors in determining the toxicity of SiO2 in vivo, as 
reflected by MTD, and the equivalent total surface area dosing strategy should be 
applicable to SiO2 without the presence of functional silane on the surface. 
4.5 Conclusion 
Of the materials studied here, nonporous SiO2 sized 120 nm exhibited low 
systemic toxicity and the highest MTDs of 450 mg/kg before or after primary amine 
modification when exposed intravenously to animals. Mesoporous SiO2 exerted 
considerable systemic toxicity with MTDs ranging from 30 – 65 mg/kg, irrespective of 
the geometrical features. However, toxicity was attenuated when mesoporous SiO2 were 
modified with primary amine functionalities, which led to the increased MTDs of 100 – 
150 mg/kg. In vivo toxicity of SiO2 was mostly influenced by nanoparticle porosity and 
surface characteristics, and was primarily associated with vasculature obstruction as a 
consequence of SiO2 protein interaction and change in hydrodynamic size in the serum.  
Dosing SiO2 on an equivalent total surface area basis could achieve a common mode of 
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action as was quantitated as MTD here. Further studies will be focusing on the 
pharmacokinetics and tissue distribution of SiO2 with distinct physicochemical features to 
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IN VIVO BIODISTRIBUTION AND PHARMACOKINETICS OF  
SILICA NANOPARTICLES AS A FUNCTION OF GEOMETRY,  
POROSITY, AND SURFACE CHARACTERISTICS 
5.1 Introduction 
Nanoparticle physicochemical properties, such as size, pegylation, and surface 
charge, play important roles in biodistribution and in vivo toxicity of SiO2 [1-5]. It has 
been reported that mesoporous SiO2 of smaller size with surface pegylation had lower 
capture by the RES and were more slowly degraded [6]. Organically modified silica 
nanoparticles with diameters of 20 – 25 nm exhibited effective clearance via the 
hepatobiliary route without any sign of organ toxicity [7]. Cationic mesoporous SiO2 
were excreted rapidly by the hepatobiliary route, probably due to charge-dependent 
serum protein adsorption [8]. Limited information, however, is available about the impact 
of geometry of SiO2 on biodistribution and toxicity.  
In previous chapters, studies on lung cancerous epithelial cells and macrophages 
showed that in vitro toxicity of spherical or rod-shaped SiO2 was mainly determined by 
porosity and surface characteristics irrespective of geometric features [9]. Further in vivo 
studies demonstrated that the systemic toxicity of these nanoparticles was also mainly 
influenced by nanoparticle porosity and surface characteristics. Mesoporous SiO2 tended 




nanoparticles improved the tolerated dose threshold [10]. Geometry did not make a 
significant difference in the mechanism or extent of the systemic toxicity. The next 
logical step is to investigate the distribution of these SiO2 in animals to shed light on the 
causes for in vivo toxicity observed in mice beyond MTDs and to relate the in vitro 
toxicity and cellular uptake with in vivo toxicity and biodistribution. In this chapter, we 
report the biodistribution and pharmacokinetics of SiO2 in mice as a function of geometry, 
porosity, and surface characteristics. 
5.2 Materials and methods 
5.2.1 Materials 
Stӧber, Meso S, AR8, and their amine-modified counterparts (SA, MA, 8A) were 
prepared as reported previously [9]. Monoiodinated Bolton-Hunter Reagent, 1 mCi/37 
MBq in benzene, was purchased from American Radiolabeled Chemicals (St. Louis, MO). 
CD-1 mouse serum was a customized bio-specimen order from Charles River 
Laboratories, from which the CD-1 mice were ordered for this study. All other chemicals 
were of reagent grade from Sigma-Aldrich.  
5.2.2 Premodification of SiO2 for radiolabeling experiments 
Cationic, amine-modified SiO2 were produced by reacting the nanoparticles with 
APTES at a weight ratio of 1:1 in anhydrous ethanol for 20 hours at room temperature as 
described previously [9]. To obtain anionic, slightly amine-modified SiO2, the same 
procedure was used except that APTES reacted with SiO2 at the weight ratio of 1:50 to 
make sure there were available primary amine groups on the surface to conjugate with 




negative. The nanoparticles were stored in ethanol and thoroughly washed in water and 
borate buffer immediately before radiolabeling experiments.  
5.2.3 SiO2 radiolabeling experiments 
The radiolabeling protocol was adapted from an established Bolton-Hunter 
method, whereby the primary amine groups available on the nanoparticle surface formed 
an amide bond with N-hydroxysuccinimide group from monoiodinated Bolton-Hunter 
Reagent [11, 12]. To react with nanoparticles, 20 µL monoiodinated Bolton-Hunter 
Reagent was transferred to a glass vial and the solvent was allowed to dry in the air for an 
extended time (1 hour). 10 mg of SiO2 prepared in the above section (10 mg/mL) in 0.05 
M borate buffer (pH 8.5) was quickly added to the glass vial and stirred on ice for 45 
minutes. Then the mixture was transferred to a dialysis cellulose ester membrane with a 
cutoff size of 3.5 – 5 kD (Float-A-Lyzer G2, Spectra/Por, Specutrum Laboratories, Inc) 
and dialyzed against 4 L water at room temperature for 20 days with water changing on a 
daily basis. The unreacted Bolton-Hunter Reagent was readily hydrolyzed in the aqueous 
medium and was removed by dialysis. The hydrolyzed product is referred to as 125I-BHR 
in this article. Thin layer chromatography (TLC) silica gel was used to check the 
presence of unbound 125I-BHR in radiolabeled SiO2 (
125I-SiO2) using methanol water (4:1 
volume ratio) solvent as the mobile phase. The radioactivity on silica gel was measured 
by the Packard Cobra auto-gamma counter (GMI, Ramsey, Minnesota). For SA and 
slightly amine-modified Stӧber, dialysis did not completely remove 125I-BHR from 
nanoparticles and thus, an alternative centrifugation method described below was used. 
The mixture from radiolabeling reaction was collected into a 2.0 mL microtube and spun 




Germany). Nanoparticles were extensively washed in water and methanol and finally in 
water. Then TLC method was applied to check the presence of 125I-BHR in nanoparticles 
from each washing cycle until unbound 125I-BHR was confirmed to be absent in 125I-SiO2. 
5.2.4 Serum stability of 125I-SiO2 
The stability of radiolabeling on SiO2 was tested in mouse serum before the 
biodistribution study. 0.5 mg 125I-SiO2 was added to 1 ml 50% CD-1 mouse serum in 
saline and incubated at 37 oC for 72 hours. The experiment was done in triplicate with 
125I-BHR in 50% mouse serum as the positive control. At the end of 72 hours, an aliquot 
of mixture was withdrawn by a glass capillary and analyzed by TLC. The stability of 125I-
SiO2 was expressed as percentage of radioactivity in the original spotting site out of the 
total radioactivity on the plate. 
5.2.5 Biodistribution and pharmacokinetic analysis 
Animal studies were conducted under an approved protocol of the University of 
Utah IACUC. Female CD-1 mice, 6 – 8 weeks old, were purchased from Charles River 
Laboratories and housed in standard cages with five animals per cage. All animals were 
acclimated to the animal facility for at least 1 week prior to experimental procedures. 
CD-1 mice were injected via the lateral tail vein with 20 mg/kg SiO2 suspension in 200 
µL sterile saline. The SiO2 suspension was a mixture of 
125I-SiO2 and SiO2 of the same 
type to make a radioactivity dose of 60,000 cpm per animal for pristine SiO2 (Stӧber, 
Meso S, AR8) or a radioactivity dose of 120,000 cpm per animal for amine-modified 
SiO2 (SA, MA, 8A). The weight content of 
125I-SiO2 which contributed to the dose of 




sacrificed at 5 minutes, 30 minutes, 2 hours, 24 hours, and 72 hours post-intravenous 
injection. At each time point, animals were terminated by CO2 asphyxiation and blood 
samples were collected via the inferior vena cava by a heparin-coated syringe 
immediately post-euthanasia. The animals were flushed with 20 mL sterile saline to 
remove blood that remained in the organs in order to obtain accurate tissue accumulation 
counts based on nanoparticle tissue association or uptake rather than blood content. 
During necropsy, organs of interest (heart, liver, spleen, lung, kidneys, brain, stomach, 
small intestine, large intestine, tail, thyroid) and the rest of the carcass (bones, muscle, 
and skin) were dissected and weighed, followed by tissue radioactivity measurement by a 
gamma counter. Radioactivity obtained from different organs was calculated as the 
percentage of the injected dose per gram of tissue. Compartmental analysis of the 
pharmacokinetic data was performed using WinNonlin Professional, version 5.3 
(Pharsight Corporation, CA). A two-compartmental pharmacokinetic model was utilized 
with first-order elimination. 
5.2.6 Urinary and hepatobiliary excretion studies 
To measure the excretion of SiO2 into urine and feces, five animals received the 
intravenous injection of SiO2 of each type at 20 mg/kg and were individually housed in 
special single-mouse metabolic cages. Urine and feces were collected into separate tubes 
at 2 hours, 24 hours, 48 hours, and 72 hours. The samples were immediately weighed and 
their radioactivity was measured by a gamma counter. In order to identify the radioactive 
species in urine, the urine samples, positive controls (950 µL normal urine + 50 µL 2.5 
mg/mL SiO2 + 5 µL 15,000 cpm 
125I-BHR), and negative controls (950 µL normal urine 




g for 20 minutes to obtain the supernatant. The supernatant was removed and measured 
by a gamma counter. The percentage of radioactivity in the supernatant out of the overall 
urine sample is indicative of percentage of unbound radioactivity or degraded product in 
the urine. 
5.2.7 Statistical analysis 
Experiments were performed in triplicate with results present as average value or 
mean ± SD. For in vivo studies, five animals were used per group and differences in in 
vivo data were analyzed using one-way ANOVA by GraphPad Prism (GraphPad 
Software, CA). Where detected, Tukey’s test was used to evaluate pairwise differences 
between the groups.  
5.3 Results 
Stӧber, Meso S AR8 were previously synthesized and stored in ethanol[9]. The 
pristine SiO2 were further modified with APTES to obtain their highly cationic 
counterparts (SA, MA, 8A). These amine-modified SiO2 were directly used in 
radiolabeling experiments for SA, MA, and 8A. To track the distribution of pristine SiO2 
in vivo, the SiO2 were slightly modified with APTES to generate available primary amine 
groups for radioisotope conjugation while the anionic surface charge was maintained for 
comparison with highly cationic, amine-modified SiO2 in this study (Figure 5.1). The 
content of unbound 125I-BHR in the 125I-SiO2 product post-purification was analyzed by 
TLC. There was minimum presence of unbound radioisotope molecules associated with 
125I-SiO2 product (Figure 5.2). Serum stability study on a typical 
125I-SiO2, 
125I-MA, 








Figure 5.1 Schematic illustration of nanoparticle selection, radiolabeling, and animal 
















Figure 5.2 TLC analysis of A) 125I-BHR (positive control), or 125I-SiO2 with various 
physicochemical properties, B) 125I-Meso S, C) 125I-MA, D) 125I-AR8, E) 125I-8A, F) 125I-
Stӧber, G) 125I-SA post-purification. Results show that there were minimum unbound 




mouse serum at 37 oC for 72 hours (Figure 5.3). 
Biodistribution of a series of SiO2 with varied shapes, porosities, and surface 
characteristics was evaluated in immune-competent CD-1 mice via bolus tail vein 
injection by tracing the radioactivity distribution. Results show that SiO2 of various 
physicochemical properties mainly accumulated in the liver and spleen with differential 
distribution into the lung (Figures 5.4-5.9). To evaluate the effect of geometry on 
biodistribution, spherical mesoporous SiO2 (Meso S, MA) were compared with rod-
shaped mesoporous SiO2 with an aspect ratio of 8 (AR8, 8A). Both Meso S and AR8 
exhibited extensive lung accumulation. This accumulation was almost eliminated with 
amine-modified nanospheres MA but not with amine-modified nanorods 8A. All the 
accumulation in the lung showed a rapid elimination from this organ within 24 hours 
post-injection. To examine the influence of porosity on nanoparticle biodistribution, 
mesoporous nanospheres (Meso S) were compared with nonporous nanospheres (Stӧber). 
Results show that Meso S was primarily accumulated in the lung while Stӧber had 
negligible accumulation in this organ. Stӧber also exhibited an increased percentage of 
liver accumulation out of total recovered dose compared with Meso S. To analyze the 
surface modification effect, amine-modified SiO2 were compared with their pristine 
counterparts. It was revealed that amine modification could efficiently reduce 
nanoparticle lung accumulation (Figures 5.4-5.9).  
The blood profiles of SiO2 were fitted to a two-compartmental pharmacokinetic 
model. All nanoparticles studied were rapidly cleared from blood circulation within 2 
hours of injection followed by a slow elimination phase which indicated the slow re-




Figure 5.3 Serum stability of 125I-BHR (positive control) and 125I-SiO2 post-incubation 
with 50% mouse serum at 37 oC for 72 hours analyzed by TLC. Results are expressed as 
percent of radioactivity at different locations from original spotting point out of the total 



















Figure 5.4 Biodistribution of Meso S in healthy mice post-bolus tail vein injection at a 
















Figure 5.5 Biodistribution of MA in healthy mice post-bolus tail vein injection at a dose 

















Figure 5.6 Biodistribution of AR8 in healthy mice post-bolus tail vein injection at a dose 

















Figure 5.7 Biodistribution of 8A in healthy mice post-bolus tail vein injection at a dose 

















Figure 5.8 Biodistribution of Stӧber in healthy mice post-bolus tail vein injection at a 
















Figure 5.9 Biodistribution of SA in healthy mice post-bolus tail vein injection at a dose 


















Figure 5.10 Two-compartmental pharmacokinetic analysis of SiO2 biodistribution: A) 
Meso S, B) MA, C) AR8, D) 8A, E) Stӧber, F) SA in healthy mice. Activity in the blood 
is converted to nanoparticle concentration using percent injected dose per gram blood and 






significant difference in the terminal clearance rates of various types of SiO2 (p > 0.05) 
(Figure 5.11). Stӧber showed a significantly higher volume of distribution at steady state 
(Vss) than Meso S (p < 0.05), while amine-modified, spherical SiO2 (MA, SA) exhibited a 
significant increase in Vss compared to their pristine counterparts (Meso S, p < 0.01; 
Stӧber, p < 0.001) (Figure 5.12).  
The tissue affinity indices, calculated as the ratio of area under the curve from a 
specific organ over area under the curve of blood, reflect the affinity and capacity of 
nanoparticle association with the specific organ of interest [15]. Various SiO2 showed 
high affinity for the spleen and low affinity for the kidneys across the board (Table 5.1). 
High aspect ratio 8A showed on average higher lung affinity than MA. Stӧber and SA 
had on average higher liver uptake than mesoporous nanoparticles with or without amine 
modification.  Mesoporous SiO2 showed on average higher affinity to the lung than 
Stӧber. The lung exposure was drastically reduced by amine modification as indicated by 
decreased tissue affinity indices from amine-modified nanoparticles (SA, MA, 8A) 
compared with their pristine counterparts (Stӧber, Meso S, AR8). The same trend was 
also observed for kidney exposure of various SiO2. 
The tissue/blood concentration ratio of various nanoparticles in major organs, 
liver, spleen, lung, and kidneys, was used as an indicator of changes in organ 
penetrability and retention over time [16]. The SiO2 across the board generally showed an 
increase in partitioning in the liver and spleen over time (Figures 5.13-5.14), but the 
partitioning remained constant in the lung and kidneys over 72 hours (Figures 5.15-5.16). 





Figure 5.11 Pharmacokinetic parameter clearance based on the two-compartmental 
analysis for the nanoparticles. There was no significant difference in clearance among all 




















Figure 5.12 Pharmacokinetic parameter Vss based on the two-compartmental analysis for 
the nanoparticles. Amine-modified SiO2, MA or SA, exhibited significantly higher Vss 
than their pristine counterparts, Meso S (**p < 0.01) or Stӧber (***p < 0.001). Stӧber 
showed a significantly higher Vss than Meso S (
*


















Tissue affinity indices of SiO2 of various geometries, porosities, and surface 
characteristics in major organs of CD-1 mice. 
 
  Tissue affinity index  
Treatment Liver Spleen Lung Kidneys 
Meso S 46.9 93.5 138.9 3.2 
MA 82.9 172.3 1.4 0.8 
AR8 80.7 193.9 41.8 3.4 
8A 49.4 180.5 17.2 2.0 
Stӧber 186.0 148.1 6.0 3.6 





















Figure 5.13 Tissue/blood concentration ratio of various SiO2 in liver. Data are presented 




















Figure 5.14 Tissue/blood concentration ratio of various SiO2 in spleen. Data are 



















Figure 5.15 Tissue/blood concentration ratio of various SiO2 in lung. Meso S showed a 
significantly higher lung/blood concentration ratio than Stӧber (***p < 0.001) or MA (***p 



















Figure 5.16 Tissue/blood concentration ratio of various SiO2 in kidneys. Data are 


















lung/blood concentration ratio than Stӧber (p < 0.001) or MA (p < 0.001) over 3 days 
(Figure 5.15). 
Excretion of the radioactive material through urinary or hepatobiliary routes 
followed a similar pattern where radioactivity was excreted through urine more than feces 
at all time-points (2 hours, 24 hours, 48 hours, and 72 hours) and the excretion peaked at 
24 hours post injection for both routes (Table 5.2). The overall excreted radioactivity 
reached 15% - 38% of injected dose by the end of study. To investigate the radioactive 
species in the excrement, we centrifuged down the urine samples as well as various 
controls mentioned in the method section to identify radioactive material in the 
supernatant (Figure 5.17). Results from control groups show that 125I-BHR did not have 
physical adsorption with SiO2 and 100% was recovered in the supernatant while 4% of 
125I-AR8, a typical 125I-SiO2, was recovered in the supernatant. This indicates that the 40% 
recovered radioactivity in supernatant of urine samples from AR8 treatment in mice was 
most likely to be unbound radioisotopes or small 125I-SiO2 degraded product. Similar 
results were found for urine samples from other nanoparticle treatment groups. We also 
collected the feces from nanoparticle treated animals, suspended in saline followed by 
centrifugation. Results showed that at least 36% radioactivity in feces was from unbound 
radioisotopes or small degraded product. The rest of radioactivity recovered in the pellet 
of urine or feces samples post-centrifugation could be 125I-SiO2 or their relatively large 
degraded product [17]. 
5.4 Discussion 
In this chapter, the effect of geometry, porosity, and surface characteristics of 




Table 5.2 Urinary or hepatobiliary excretion of radioactivity post-intravenous injection 




2 hours 24 hours 48 hours 72 hours 2 hours 24 hours 48 hours 72 hours 
Meso S 1.4 ± 1.4 7.6 ± 2.1 10.2 ± 2.8 13.0 ± 3.3 0.1 ± 0.1 5.1 ± 1.4 7.0 ± 2.6 8.5 ± 2.5 
MA 4.4 ± 1.9 10.9 ± 3.4 12.4 ± 3.5 14.8 ± 4.3 0.2 ± 0.1 3.4 ± 1.8 4.3 ± 2.1 5.5 ± 2.8 
AR8 1.0 ± 1.0 16.6 ± 8.9 18.9 ± 9.0 22.7 ± 10.9 0.1 ± 0.1 11.1 ± 4.2 12.8 ± 4.5 15.4 ± 4.8 
8A 5.1 ± 3.3 18.4 ± 5.5 20.4 ± 5.4 21.9 ± 5.5 0.1 ± 0.1 9.5 ± 2.8 10.6 ± 3.0 12.9 ± 4.1 
Stӧber 3.7 ± 1.4 9.5 ± 2.1 11.7 ± 2.4 13.5 ± 2.8 0.5 ± 0.3 7.0 ± 1.3 8.9 ± 1.9 11.6 ± 1.6 
SA 2.7 ± 0.9 7.7 ± 3.0 9.0 ± 3.3 10.6 ± 2.9 0.1 ± 0.1 2.4 ± 0.7 3.7 ± 0.6 5.2 ± 0.9 
aExcretion is expressed as percent radioactivity in urine or feces out of the total 























Figure 5.17 The percentage of radioactivity in the supernatant of different groups post-
centrifugation. Results are expressed as percent of radioactivity in the supernatant post-
centrifugation out of the total radioactivity in the microtubes. Data are presented as mean 















mice was evaluated. The overall effect of physicochemical parameters of nanoparticles 
on the studied biological systems is summarized in Table 5.3 to enable the relation of 
biodistribution patterns observed here with cellular uptake and toxicity profiles of similar 
nanoparticles observed in previous chapters [9, 10].  
The biodistribution results show that the majority of SiO2 accumulated in the liver 
and spleen post-injection (Figures 5.4-5.9). This is due to the fact that the discontinuous 
endothelium lining the sinusoidal walls of the liver and spleen allows the passive 
entrapment of foreign particulates [14, 18]. The continuously increased organ/blood 
concentration ratios for the liver and spleen indicate that nanoparticles were internalized 
post-physical sequestration due to the prevalent presence of macrophages in these organs 
(Figures 5.13-5.14). The difference in accumulation of SiO2 in various organs 
corroborates with our previous in vitro studies which showed that the cellular response to 
nanoparticle exposure was cell-type-dependent; macrophages had extensively higher 
association with the nanoparticles than epithelial cells [9]. Thus, the liver and spleen, 
where most macrophages reside, showed the most extensive SiO2 accumulation in the 
biodistribution study.  Nonporous SiO2 (Stӧber) and their amine-modified counterparts 
(SA) exhibited the highest liver affinity among all types of nanoparticles (Table 5.1). 
These results agree with in vitro studies which showed that porosity played a major role 
in determining nanoparticle cellular association; nonporous nanoparticles with or without 
amine modification had the highest cellular association among all types of nanoparticles 
[9]. The high affinity of Stӧber for liver could be responsible for the significant increase 
in liver enzyme levels in plasma beyond MTDs compared with controls, as shown in 





Summary of engineered SiO2 with various physicochemical properties and their in vitro 
and in vivo evaluation results  
 




Geometry by TEM (nm) 115 120 136 × 
1028 














Surface charge in water ---- --- --- ++ +++ +++ 
DLS size in serum (nm) 121.6 268.9 N/A N/A 150.3 N/A 
In vitroa IC50 
(µg/mL) 
M 73 89 74 254 182 225 





M 21.2 0.7 0.4 14.8 3.3 4.1 
E 1.5 0 0 1 0.4 0.8 















Geometry / / / / / Lung 










/ / / 
Pharmaco-
kinetics 
Vss (L) 0.2 0.09 0.07 0.37 0.23 0.09 
acontent adapted from reference [9], surface charge is ranked as ---- highly negative -60 – -40 mV, --- highly negative -
40 – -30 mV, ++  moderately positive 10 – 20 mV, +++ highly positive 20 – 40 mV. N/A means not available. M or E 
refers to macrophages RAW 264.7 or cancerous epithelial cells A549, / means not observed in the study design. 
bcontent adapted from reference [10], for column under biodistribution, it means that the physicochemical property 
(indicated in the corresponding column) of nanoparticles of a specific type (indicated in the corresponding row) led to 
higher affinity in specific organs (indicated in the crossed cell) than nanoparticles of correspondingly different property 
(nonporous versus mesoporous, pristine versus amine-modified, or nanospheres versus nanorods). / means that this 










influencing the nanoparticle biodistribution pattern. 
The SiO2 of various types exhibited differential accumulation in the lung post-
injection (Figures 5.4-5.9). The constant lung/blood concentration ratio over time 
indicated that the accumulation of SiO2 in the lung was because of transient association 
with capillary rather than internalization (Figure 5.15). The association was balanced 
between SiO2 organ concentration and SiO2 blood concentration by SiO2 translocation 
and redistribution into other organs. Thus, the accumulation in the lung was mostly in 
capillaries rather than in pulmonary cells. Mesoporous SiO2 exhibited a higher lung 
affinity than nonporous SiO2, and amine modification reduced lung affinity compared 
with the pristine SiO2 (Figure 5.15). This pattern could be related to the changes in 
nanoparticle hydrodynamic size in the presence of serum (Table 5.3). Though produced 
with similar size as confirmed by TEM, mesoporous SiO2 had significantly higher 
hydrodynamic size in the serum, probably due to protein adsorption, than nonporous SiO2 
which were probably stabilized by protein adsorption as suggested previously [10]. The 
relatively large hydrodynamic size of mesoporous SiO2 in serum can partially explain the 
increased lung accumulation compared with nonporous SiO2 (Figures 5.4, 5.8). Since the 
lung has the most abundant blood supply among all major organs, nanoparticles with 
larger hydrodynamic size are more likely to cause obstruction in vessels and increase 
organ accumulation. The amine-modified SiO2 showed smaller hydrodynamic sizes in 
serum, probably due to steric stabilization from adsorbed protein molecules, than their 
pristine counterparts [10], which causes lower pulmonary accumulation (Figures 5.5, 5.7, 
5.9) and decreased tissue affinity indices (Table 5.1). However, amine-modified 




nanospheres (MA) (Table 5.1), demonstrating that geometry of these nanoparticles 
influences biodistribution to a certain extent. In all, lung accumulation of nanoparticles 
was mostly influenced by porosity and surface characteristics; however, elongated 
geometrical shape (rods versus spheres) increased accumulation in this organ for amine-
modified SiO2. 
Our previous in vivo toxicity studies showed that the onset of adverse reactions 
was mainly due to the mechanical obstruction of nanoparticles in the vasculature that led 
to congestion in organs and subsequent functional failure [10]. It appears that it is the 
“vasculature impact” rather than cellular toxicity that limits silica nanoparticle safety in 
vivo. In in vitro studies, nanoparticle toxicity was mainly influenced by surface 
characteristics; primary amine modification significantly reduced cellular toxicity, as 
shown by the increased IC50 values compared with pristine nanoparticles, probably due to 
the differential subcellular localization, whereas porosity and geometry did not seem to 
affect the IC50 [9]. In in vivo studies, porosity and surface characteristics influenced 
hydrodynamic sizes of SiO2 in circulation, which had an important implication in their 
vasculature impact and resultant tolerance threshold [10]. Lung and kidneys were shown 
to be most susceptible to nanoparticle obstruction in vasculature above MTDs, probably 
due to their abundant blood supply and special anatomic structures [10]. Mesoporous 
SiO2, which potentially had the largest hydrodynamic size in circulation as evidenced by 
hydrodynamic size analysis in serum, were most prone to cause vasculature obstruction 
and subsequent renal failure, resulting in the lowest MTDs at 30 -45 mg/kg irrespective 
of geometrical features [10]. Amine modification on mesoporous SiO2 reduced the 




SiO2 had the smallest hydrodynamic size in serum and thus reached the highest MTDs at 
450 mg/kg, as observed previously [10]. These previous observations show that porosity 
and surface characteristics are major factors that influence in vitro or in vivo toxicity of 
SiO2. Our current studies evaluating the biodistribution of these nanoparticles also 
ascertain the predominant effects of porosity and surface characteristics on organ 
accumulation. 
Pharmacokinetic analysis demonstrates that the majority of SiO2 of all types were 
rapidly cleared from circulation at a similar rate (Figure 5.11). Pristine SiO2 had lower 
Vss than the amine-modified counterparts while nonporous SiO2 showed higher Vss than 
mesoporous SiO2 (Figure 5.12). This agrees with previous in vitro studies on both 
macrophages and epithelial cells that mesoporous SiO2 had lower cellular association 
than their amine-modified counterparts while nonporous SiO2 showed higher association 
than mesoporous SiO2 [9]. These in vivo observations suggest that amine-modified SiO2 
or nonporous SiO2 tended to associate and be taken up by RES in liver or spleen, leading 
into increased Vss.  
Further excretion experiments showed that radioactivity originally from 125I-SiO2 
dosed intravenously was found in urine and feces (Table 5.2), indicating possible 
excretion of SiO2 or their degraded product. Nanoparticle accumulation in the kidneys 
was low (Figures 5.4-5.9) and there was limited affinity of SiO2 to this organ (Figure 
5.16). Due to the very dilute radioactivity concentration in urine and low loading capacity 
of TLC assays, we could not quantitatively identify each radioactive species in the urine 
by TLC. Based on the centrifugation method, it was showed that there was possible 




possible unbound radioisotopes from bond breakage from 125I-SiO2 in vivo was detected 
in supernatant of urine (Figure 5.17). It is possible that nanoparticles were degraded into 
orthosilicic acid species smaller than the reported renal excretion threshold of 7 nm, and 
were cleared through the renal route [4, 19]. Previous studies by Tang’s group have 
suggested that intact SiO2 larger than 100 nm in size can be excreted in urine post-
intravenous injection, as evidenced by TEM imaging [20]. The mechanism of large 
nanoparticle excretion into urine is not fully understood and warrants further studies. The 
examination into radioactivity in feces indicated a similar fact that SiO2 was likely 
excreted through hepatobiliary route into feces as the dense silicate form present in the 
pellet of feces from centrifugation method, which agrees with previous studies by Lo’s 
group that reported the hepatobiliary excretion of SiO2 by fluorescence imaging [8]. Our 
results from excretion experiments suggest that SiO2 could be biodegraded and excreted 
out of the body. 
5. 5 Conclusion 
Of the materials tested in this study, it was demonstrated that SiO2 biodistribution 
was influenced more by nanoparticle porosity and surface characteristics, and less by 
geometry. The nanoparticles across the board showed extensive distribution into the liver 
and spleen with different concentrations in the lung. Mesoporous SiO2 accumulated in the 
lung to a higher extent than nonporous SiO2 of similar size. Such accumulation was 
reduced by primary amine modification. However, high aspect ratio amine-modified 
nanorods showed higher lung accumulation than the amine-modified nanospheres. 
Results from tissue affinity indices and tissue/blood concentration ratio kinetic analyses 




Nonporous SiO2 exhibited high affinity to the liver, and mesoporous SiO2 had higher 
affinity to the lung. Amine modification reduced the affinity of SiO2 to the lung and 
kidneys. Two-compartmental pharmacokinetic analysis showed that amine-modified SiO2 
tended to have higher Vss than the pristine counterparts and that nonporous SiO2 
exhibited a higher Vss than mesoporous SiO2. SiO2 could be degraded and excreted out of 
the body by both urinary and hepatobiliary routes. This study enables the systematic 
understanding of how physicochemical factors affect the living system and facilitates the 
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CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Conclusions 
Porosity and surface characteristics played crucial roles in determining SiO2 
impact on the biological systems. Toxicity was affected to a lesser extent by geometry. 
Porosity influenced nanoparticle cellular association as nonporous SiO2 had higher 
association than mesoporous SiO2. Porosity also influenced the hydrodynamic size in 
serum and in turn determined the vasculature impact and the safety dose level. 
Nonporous SiO2 had a lower hydrodynamic size in serum and was much better tolerated 
than mesoporous SiO2 of similar sizes. Porosity played a critical role in determining the 
biodistribution and pharmacokinetics of SiO2 in major organs. Mesoporous SiO2 had 
higher lung affinity than nonporous SiO2, possibly due to larger hydrodynamic size. 
Nonporous SiO2 had higher liver affinity and Vss than mesoporous SiO2, probably 
because of higher cellular association with the RES. Surface characteristics was the 
predominant factor that determined the cellular toxicity and association extent in vitro. 
Amine modification on mesoporous SiO2 increased the cellular association on both 
macrophages and epithelial cells. However, it significantly reduced the cellular toxicity, 
probably due to differential cellular localization compared with pristine SiO2. Surface 
characteristics also determined in vivo nanoparticle safety level, biodistribution, and 
pharmacokinetics. Amine-modified SiO2 showing a lower hydrodynamic size than 
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pristine SiO2 led to increased MTDs and reduced affinity to lung and kidneys. Amine-
modified SiO2 also showed a higher Vss, probably due to increased association with the 
RES. Geometry did not seem to play a vital role in determining the cellular uptake, in 
vitro toxicity, and in vivo toxicity. However, high aspect ratio 8A did show increased 
lung accumulation compared with MA, which indicates the influence of geometry of 
amine-modified nanoparticles in biodistribution. The molecular mechanisms of these 
geometry, porosity, and surface modification effects need further detailed examination. 
6.2 Future directions 
The long-term objective of this research is to exploit the effect of 
physicochemical properties of SiO2 on the biologically relevant environment to provide a 
rational design of SiO2 for their intended applications. Owing to their high surface areas 
and ordered mesoporous structure, mesoporous silica materials constitute an interesting 
drug carrier for non-water-soluble drugs as it allows the control of the kinetic delivery of 
lipophilic drugs [1]. It has been reported that the physicochemical characteristics of silica 
matrices have substantial influence on drug loading and release profiles [2-4]. Linden’s 
group found that the loading degree is related to the surface area and pore size of the 
silica matrix and the release kinetics is mainly dependent on porosity [3]. One-
dimensional pore structure with cage-like pores is the most promising pore geometry to 
provide slow release of drugs for time periods varying from hours to weeks [3]. Vallet-
Regi’s group reported that amine-functionalized MCM-41 microspheres showed a 
significantly slower drug release rate than irregularly shaped silicate powders, which 
should facilitate drug delivery over a longer time [4]. Since we have already covered the 
baseline study on the toxicity and biodistribution of the nanocarrier as a function of 
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geometry, porosity, and surface characteristics, it is logical to analyze the influence of 
these characteristics on the drug loading or release profiles for the intended biomedical 
application. To achieve this goal, ibuprofen, a poorly aqueous soluble molecule, is chosen 
as the model drug. Engineered SiO2 were loaded with ibuprofen by soaking them into the 
pentane solution of ibuprofen under continuous stirring at 37 oC. The loaded sample was 
recovered by filtration, washed with pentane, dried, and compacted to obtain disk pieces. 
Thermogravimetric and elemental analysis will be used to measure the drug loading in 
the sample. The ex vivo drug release analysis will be conducted by soaking the sample 
disks into the simulated body fluid at 37 oC under continuous stirring. The released 
ibuprofen concentration will be monitored by UV spectrometry at 273 nm [4]. It is 
expected that the surface characteristics, porosity, and geometry will have significant 
influence over drug loading and release from nanoparticles. 
In vitro study has shown that amine-modified SiO2 reduced toxicity to exposed 
cells compared with the pristine counterparts. It is very important to look into the cause 
for this toxicity reduction as it is against the main stream knowledge that amine 
modification on the nanosystem increases toxicity in cells as reported by previous 
literature [5, 6]. This investigation is crucial for understanding the interaction of 
nanoparticles with biological systems and which factors, such as amine moiety, 
interaction of amine groups with nanoparticle surface, surface charge, protein 
opsonization, etc., determine the consequences of nanoparticle exposure to biological 
systems. To accomplish this, the nanoparticles could be modified with different amounts 
of primary amine groups to obtain different zeta potentials. The proliferation inhibition 
assay can be performed. IC50 can be obtained to evaluate the cytotoxicity level of 
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nanoparticles with different charges. We expect that there is a charge threshold beyond 
which the nanoparticles start to show reduced IC50 compared with the pristine 
counterparts. To explain the changes in IC50, nanoparticles will be fluorescently labeled 
to allow imaging by confocal microscopy. It is expected that the differential cellular 
uptake pathway and subcellular location of nanoparticles causes the difference in IC50. 
In vivo toxicity study revealed that the mechanism of adverse reaction in animals 
was mostly due to obstruction of nanoparticles in vasculature rather than cellular toxicity. 
It is crucial to analyze the nanoparticle interaction with whole blood which directly 
reflects a nanoparticle’s status in the circulation when injected intravenously. Platelet 
aggregation studies and neutrophil activation experiments can be performed. Hageman 
factor- and tissue factor-dependent activation of human blood/plasma coagulation, and 
binding to human monocytes, endothelial cells, and platelets, can be quantified in vitro 
for various SiO2. This study could screen nanoparticles with different characteristics to 
select hemocompatible medical nanodevices for the intravenous route [7]. 
Since in vivo biodistribution study showed the presence of radioactivity in urine 
and feces and it has been reported previously that nanoparticles with sizes larger than 100 
nm could be found as an intact modality in excrement [8, 9], it is necessary to evaluate 
the mechanism of how these large nanoparticles could be excreted intact considering the 
renal threshold of several nanometers [10]. Since the biodistribution was done at 20 
mg/kg, which was below the MTD of all SiO2, no histological abnormality was found in 
kidneys [11]. It is very interesting to analyze the clearance pathway of large size 
nanoparticles when no physiological damage was seen in kidneys. TEM images could be 
obtained for kidneys of animals post-intravenous injection of SiO2 to analyze the possible 
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presence of intact nanoparticle in the exit route and connect with the physiological status 
of nephron. This study could generate important data about clearance and 
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CHARACTERIZATION AND CYTOTOXICITY OF 
SILICA NANOTUBES 
A.1 Introduction 
Silica nanotubes (SNTs) are a novel class of inorganic structures with potential 
applications in imaging and drug delivery [1-10]. The hollow tubular structure obtained 
with template synthesis [4, 5, 9] can be differentially functionalized on the inner or outer 
surfaces, enabling the loading of biomolecules inside the tubes and the outer surface 
modification for targeting or solubility purposes. The open ends of tubes can be 
functionalized with stimuli-sensitive polymers to act as selective gates to regulate the 
release of biomolecules based on environmental conditions. 
Despite the unique advantages of SNTs, how they interact with biological systems 
remains largely unknown. Previously, it was shown that SNTs are internalized by cells 
and that nanotube size and surface charge play crucial roles in determining the extent of 
cellular uptake [11]. In this pilot study, we aimed to understand the influence of size and 







A.2.1 SNT characterization  
The SNTs were provided by Professor Sang Bok Lee at the University of Maryland, 
College Park. The zeta potentials of SNTs were measured using a Nanosizer (Malvern, UK). 
Smoluchowski’s model was utilized to calculate zeta potential values from SNTs’ 
electrophoretic migration rates. The SNTs were dispersed in water at a concentration of 2.5 
g/ml with pH of the solution adjusted to 7.4 by adding 1 N HCl or 1 N NaOH and were 
subject to 10-15 minutes sonication immediately before the measurements. Experiments were 
done in triplicate and the averaged results are shown. 
A.2.2 Cell culture 
Human embryonic kidney cells HEK 293T, human large cell lung carcinoma cells 
H460, human lung fibroblast cells WI-38, and human mammary breast epithelial cells MCF 
10A were used in this study. All four cell lines were kindly provided by the late Dr. Angelika 
Burger (Greenebaum Cancer Center, University of Maryland, Baltimore, MD).  HEK 293T 
cells were cultured in DMEM supplemented with 2 mM L-glutamine, 10% FBS, penicillin, 
and streptomycin (100 U/ml and 0.1 mg/ml, respectively). H460 cells were cultured in RPMI 
medium supplemented with 2 mM L-glutamine, 10% FBS, penicillin and streptomycin (100 
U/ml and 0.1 mg/ml, respectively). WI-38 cells were maintained in RPMI medium 
supplemented with 2 mM L-glutamine, 10% FBS, penicillin, and streptomycin (100 U/ml and 
0.1 mg/ml, respectively). MCF 10A cells were maintained in mammary epithelial basal 
medium (Clonetics, Walkersville, MD) with bovine pituitary extract (52 g/ml), 
hydrocortisone (0.5 g/ml), human recombinant epidermal growth factor (10 ng/ml), and 
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bovine insulin (5.0 g/ml) (Clonetics, San Diego, CA). All cells were cultured at 37C in a 
humidified atmosphere of 5% CO2. 
A.2.3 Cytotoxicity assays 
Cells were seeded at a density of 2000 to 10,000 cells per well (100 l cell 
suspension) into a 96-well plate. Cells were allowed to adhere for 24 hours before the 
complete media was replaced with media containing SNTs at different concentrations (0.005 
g/ml, 0.05 g/ml, 0.5 g/ml, and 5 g/ml, quadruplicate for each concentration). Cells were 
then exposed to the incremental concentrations of SNTs for the following 72 hours at 37°C in 
a humidified 5% CO2 atmosphere. After that, the cell media were decanted and MTT solution 
was added (0.5 mg/ml in the media, 100 l media per well) into each well. The cells were 
incubated for an additional 4 hours at 37C in a humidified 5% CO2 atmosphere. 100 l to 
200 l of DMSO was added to dissolve all the formazan crystal. The optical density at 550 
nm was measured by SpectraMax M2 microplate reader (Molecular devices, CA) and the 
viability of the cells was calculated as a percentage of viability of cells grown in complete 
media in the absence of SNTs.  
 Plasma membrane integrity was assessed by using Cytoscan-lactate dehydrogenase 
(LDH) Cytotoxicity Assay Kit (Geno Technology Inc., St. Louis, MO). Exponentially 
growing MCF 10A cells were exposed to increasing concentrations of SNTs for 24 hours as 
described above. 10 µl of lysis buffer (9% v/v Triton X-100) was added to cells in positive 
control group. After incubating at 37 °C for 45 minutes, the plate was centrifuged at 250 × g 
for 5 minutes. 50 l of supernatant was used for LDH analysis following the manufacturer’s 
instruction and the absorbance was recorded at 490 nm with a reference wavelength of 680 
nm [12]. Toxicity of SNTs was calculated as follows: 
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                                    Asample - Aspont 
LDH release (%) =                                100% 
                                      Amax - Aspont 
where Asample is the absorbance of a sample exposed to SNTs, Aspont is the absorbance of a 
sample exposed to complete cell media only, and Amax is the absorbance of a sample lysed by 
lysis buffer (9 % v/v Triton X-100). 
 LDH absorption was assessed to evaluate the potential interaction of LDH enzyme 
with SNTs in the cell lysates of MCF 10A cells. Initially, MCF 10A cells were seeded at 
10000 cells/well in a 96 well plate as described above. After 24 hours, 10 l of lysis buffer 
was added and incubated with cells for 45 minutes at 37
o
C. Then the plate was centrifuged at 
250 × g for 5 minutes and 50 l of supernatant was transferred to a fresh 96 well plate and 
incubated with four types of SNTs at the concentration of 5 g/ml for 24 hours at 37°C, 5% 
CO2. After further centrifugation at 250 × g for 5 minutes, 50 l of supernatant was utilized 
to determine the LDH release of each type of SNTs following the manufacturer’s protocol. 
Absorbance was recorded at 490 nm with a reference wavelength of 680 nm. 
A.2.4 Statistical analysis 
Unless otherwise stated, all experiments were conducted in quadruplicate and the 
results were reported as means  SD, where statistical significance was determined by two-





A.3 Results and discussion 
A series of SNTs of two discrete lengths, namely, 200 and 500 nm, and two different 
surface charges, namely, unmodified bare (negatively charged) and 3-aminopropyl 
trimethoxysilane (APTS) modified (positively charged) were previously fabricated and 
characterized (Figure A.1) [11]. The zeta potentials of the materials at pH 7.4 were shown in 
Table A.1. Bare SNTs have silanol groups (Si-OH) present on the outer surface and display 
negative charge due to dissociation of protons from the surface silanol groups at pH values 
above the isoelectric point (pH 2) in an aqueous solvent [13]. As expected, 200 and 500 nm 
bare SNTs showed highly negative zeta potential values, implying that the unmodified 
nanotubes were generally stable and well dispersed in the media. APTS modified SNTs 
showed almost neutral or positive zeta potential values. APTS modified 200 nm SNTs 
showed a relatively high positive value, suggesting that these tubes are fairly stable in 
aqueous solvents. It has been shown [14] that the large aspect ratio of nanotube structures 
would generally favor increased hydrophobicity and van der Waals interactions, leading to 
aggregation and sedimentation. In contrast, the limited aggregation tendency of SNTs in 
aqueous systems is primarily attributed to electrostatic repulsion of like charge on the surface 
of SNTs. Furthermore, the silanol groups of bare SNTs can readily form the hydroxyl layer 
with water molecules through hydrogen bonding, which further improves their aqueous 
dispersibility.  
The effect of nanotubes of varying lengths and surface charge on cellular toxicity was 
determined on a panel of normal cell lines, including embryonic kidney cells (HEK 293T), 
lung fibroblasts (WI-38), breast epithelial cells (MCF 10A), as well as a cancerous cell line, 




Figure A.1 TEM images of A) 200 nm SNTs and B) 500 nm SNTs (provided by 

















Table A.1 Zeta potential of SNTs (2.5 g/ml) in deionized water, pH 7.4 
Type of SNTs Zeta potential (mV) 
200 nm bare SNTs -26.80  0.61 
200 nm APTS-modified SNTs 8.51  0.31 
500 nm bare SNTs -24.70  1.48 























was that these cells could be potentially encountered by SNTs in the in vivo biological milieu. 
A range of concentrations of SNTs (5-0.005 µg/ml) were studied. Based on the results of the 
MTT assay (Figure A.2), none of the four types of SNTs substantially affected the viability of 
the four cell lines at all concentrations tested after 72-hour exposure (over 55% or higher 
viability rates). In general, the 500 and 200 nm bare SNTs showed no significant inhibition 
on cell growth for all tested cell lines.  Surface modification resulted in moderately higher 
toxicity of APTS-modified SNTs compared with their unmodified counterparts: 200 nm 
APTS-modified SNTs demonstrated significantly higher growth inhibition compared with 
200 nm bare SNTs at 5 g/ml in HEK 293T, H460, and WI-38 cells (p < 0.05). 500 nm 
APTS-modified SNTs evoked significantly higher inhibitory effect than 500 nm bare SNTs at 
5 g/ml in WI-38 cells (p < 0.05).  
Apart from the surface charge influence, the impact of size also seems to play an 
important role on cytotoxicity evaluation: Significantly higher viability of HEK 293T cells 
and H460 cells was observed when treated with 500 nm APTS-modified SNTs compared 
with 200 nm APTS-modified SNTs at the highest concentration (p < 0.05). This suggests that 
smaller size of SNTs may be internalized to a higher extent and have greater effects on 
inhibition of mitochondrial activity. It seemed that toxicity of SNTs is cell-line-dependent: 
Statistically significant inhibition of cell growth was detected for APTS-modified SNTs in 
contrast to the unmodified counterparts in WI-38 cells at 0.05 g/ml or lower concentration 
(p < 0.05). This implies that normal lung fibroblasts are more sensitive to silica nanotube 
surfaces exposure. In all, toxicity of SNTs to different cell lines was concentration-dependent 
and toxicity was not observed higher than 45% across the panel of cell lines. Toxicity profiles 




Figure A.2 Viability of different cell lines determined by MTT assay after exposure to 500 
nm bare SNTs (), 500 nm APTS-modified SNTs (), 200 nm bare SNTs (), 200 nm 
APTS-modified SNTs () for 72 hours: A) HEK 293T cells; B) H460 cells; C) MCF 10A 
cells; D) WI-38 cells. Data presented as means ± SD (n = 4). *Statistically different (p < 













The susceptibility of fibroblast cells towards toxicity and cellular injury is increasingly being 
documented for several engineered nanoparticulate systems such as silica particles, carbon 
nanotubes [15-17]. The surface area of the particles is also believed to be an important 
parameter in determining such toxicity which is consistent with our observation with smaller 
sized SNTs (higher exposed surface area per unit dose).  
To evaluate any possible effect of surface charge on cellular membrane integrity, a 
LDH assay was performed with four types of SNTs in MCF 10A cells. The assay 
quantitatively measures the amount of stable, cytosolic, LDH enzyme, which is typically 
leaked out of cells when the cell membrane is damaged. Since all SNTs have surface charges, 
the possibility that LDH enzyme adsorbs to the surface of particles, thus leading to false 
negative cytotoxicity results, was also examined [12]. Results revealed that none of the SNTs 
tested had any significant (p > 0.05) LDH absorption at a concentration of 5mg/ml for 24 
hours (Figure A.3). LDH assays were also performed on H460 cells and no significant 
increase in LDH release was detected for all types of SNTs (data not shown).   
The 200 nm and 500 nm bare SNTs and 500 nm APTS-modified SNTs caused no 
significant increase in the LDH release at all concentrations tested after 24-hour exposure 
(Figure A.4). LDH release was observed only with 200 nm APTS-modified SNTs up to 10% 
of maximum LDH release from cells, indicating that the observed toxicity with these SNTs 
might be related to surface charge interaction with plasma membrane. Since plasma 
membrane injury is one of the physiological characteristics of necrotic cell death, LDH assay 




Figure A.3 The absorbance of LDH release from cell lysates incubated with 5 g/ml of 500 
nm bare SNTs (), 500 nm APTS-modified SNTs (), 200 nm bare SNTs (), 200 nm 
APTS-modified SNTs (), or control (cell lysates in the absence of SNTs) () for 24 hours 
in MCF 10A cells. No significant difference (p >0.05) was observed between sample 















Figure A.4 Effect of 500 nm bare SNTs (), 500 nm APTS-modified SNTs (), 200 nm 
bare SNTs (), 200 nm APTS-modified SNTs () on plasma membrane integrity of 
MCF10A cells as determined by lactate dehydrogenase (LDH) assay. Results are after 24 
hours exposure. Data presented as means ± SD (n = 4). *Statistically different (p < 0.05) from 





















In summary, SNTs of discrete length and surface charge were characterized for their 
physicochemical properties and cytotoxicity in vitro. The SNTs showed limited toxicity 
which was dependent on the cell type but also to a lesser extent on the concentration, surface 
charge, and length. These studies pave the way for understanding the structural features of 
SNTs which influence their biocompatibility in cellular environments. Such data can also aid 
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SYNTHESIS AND CHARACTERIZATION OF SILICA-COATED  
GOLD NANORODS 
B.1 Introduction 
High aspect ratio, elongated gold nanorods could absorb from the near-infrared 
through the mid-infrared light at great efficiency, which makes them suitable for multiple 
applications requiring the conversion of infrared light to heat [1]. The development in 
gold nanorods synthesis methods enabled the production of nanorods at targeted aspect 
ratios with high purity [2-8]. It has been reported that 100% high aspect gold nanorods 
could be obtained by partial dissolution of platelets [9]. Recent studies have also reported 
successful silica coating on metal nanoparticles [10, 11], which facilitates the production 
of multifunctional hybrid nanomaterials for biomedical application. 
This Appendix describes the synthesis of highly uniform silica-based nanorod 
structures for comparison with uniform silica nanospheres to evaluate the shape effect on 
biological systems. The silica coating on gold nanorods could generate high aspect ratio 
silica-coated nanomaterials as an alternative to silica nanotubes for comparative 








The gold nanorod synthesis protocol was adapted from reference [9] and the silica 
coating procedure was adapted from previous reports [10, 12]. 
Preparation of the growth solution. In a 1 L flask, 64.06 g of CTAB was 
dissolved in 880 mL water upon gentle heating at 35 oC. CTAB was dissolved in water 
upon gentle stirring, the stirring speed was kept slow so that no extensive bubbles were 
formed. In another 1 L flask, 173.4 mg of gold chloride (HAuCl4·3H2O) (weighted in 
nitrogen environment) was dissolved in 880 mL water. The CTAB solution was 
transferred into a 2 L glass bottle. The gold chloride solution was added as well. A 100 
mL flask, a 250 mL flask, and a 2 L glass bottle were collected. 45 mL of prepared 
solution was transferred into a 100 mL flask. 140 mL of prepared solution was 
transferred into a 250 mL flask. 1575 mL of prepared solution was transferred into the 2 
L glass bottle. These containers were left at room temperature (short). 0.1 M ascorbic 
acid was prepared by dissolving 176 mg of L-ascorbic acid in 10 mL of water. 0.25, 0.77 
and 8.75 mL of ascorbic acid solution was added into 100 mL, 250 mL, and 2 L container 
containing prepared solution. All three containers were hand shaken and the solution 
turned from golden to colorless.  
Preparation of the seed solution (fast). 1.47 mg of sodium citrate was dissolved in 
10 mL water. 1.97 mg of HAuCl4·3H2O was dissolved in 10 mL water. The sodium 
citrate solution and Au chloride solution were mixed together in a 150 mL flask 
containing a magnetic stirring bar. To this flask 0.6 mL of 0.1 M ice-cold sodium 




rpm. The solution became brownish-red. The seed solution was used within 10 minutes 
after preparation. 
Production of gold nanorods. 4 mL of the seed solution was added to 100 mL 
flask containing growth solution and gently mixed. Within 3 seconds, 12.4 mL of 
resulting mixture was transferred to 250 mL flask containing growth solution via a 25 mL 
plastic pipette. The mixture was gently mixed. With 3 seconds, all the content in 250 mL 
flask was transferred into 2 L glass bottle containing growth solution. The 2 L glass bottle 
was gently shaken. The glass bottle was left at 27 oC for additional 14 hours. The color of 
solution changed to purple in 2-3 minutes and then to dark red in 30 minutes. The high 
aspect ratio gold nanorods precipitated to the bottom of glass bottle within 12 hours. So 
the glass bottle was kept at 27 oC for 12 hours to 14 hours. After the settlement, all 
supernatant was carefully removed and the invisible layer of nanorods was redispersed 
into 10 mL of 0.1 M CTAB upon 30 seconds sonication.  
Partial dissolution of platelets. An oxidizing Au (III)/CTAB complex for partial 
dissolution was prepared by dissolving 364 mg of CTAB and 1.97 mg of HAuCl4·3H2O 
in 10 mL of DI water. Next, 1 mL of this solution was added to 10 mL Au nanorods and 
platelets CTAB suspension upon stirring and left undisturbed for 14 hours. Nanorods 
along with large disks precipitated and form a thin layer on the bottom of flask. The 
greenish-blue supernatnet containing small disks was carefully collected in a microtube. 
The layer of precipitate was again redispersed in 10 mL of 0.1 M CTAB solution 
followed by addition of another 1 mL of Au (III)/CTAB solution. The process was 
repeated until the supernatant of the suspension post 14 hour sedimentation was no longer 




Silica coating on gold nanorods. The Au nanorod solution (0.01 – 0.1 weight% 
nanorod concentration) was prepared. 10 µL of (3-mercaptopropyl)trimethoxysilane 
(MPTMS) solution (10 µL MPTMS in 1 mL of ethanol) was added to 1 mL of the 
nanorod solution and stirred for 20 minutes. Next, 40 µL of a 2.0 M freshly prepared 
aqueous sodium silicate solution was added and stirring continued for another 20 mintues. 
The solution was left at room temperature. 
B.2.2 Characterization 
The gold nanorods or silica coated gold nanorods were added to TEM grids and 
left dry at room temperature. TEM images were taken with a Philips Tecnai microscope 
at 120 kV. The absorbance spectrum of gold nanorods in 0.1 M CTAB/D2O solution was 
measured on a Cary-17 spectrophotometer. 
B.3 Results 
Highly uniform gold nanorods were produced at the quantity of ca. 300 µg per 
batch based on the protocol provided in the method section. The dimension of gold 
nanorods was 188.08 ± 25.12 nm × 21.89 ± 3.63 nm (length × width) (Figure B.1). The 
product was 100% nanorods without the presence of other structures (disks, platelets), 
indicating the successful removal of platelets. The Silica coating resulted in multiple gold 
nanorods uniformly coated with a silica layer of 10 nm in thickness (Figure B.2). The 
absorbance spectrum of gold nanorods in 0.1 M CTAB/D2O solution had the transverse 
peak at 524 nm (A = 0.25) and longitudinal peak at around 1400 nm to 1600 nm (A ≥ 
































Highly uniform, silica coated gold nanorods were obtained with the seed-
mediated synthesis. The size of gold nanorods was of biological relevance thus could be 
further investigated for potential application in nanomedicine. This study provides an 
effective alternative to obtain silica-based high aspect ratio nanomaterials to evaluate the 
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